Trial Outcomes & Findings for Single Rising Dose Study of MK-8723 in Healthy Participants and Participants With Immune Thrombocytopenia Purpura (MK-8723-001) (NCT NCT01963260)

NCT ID: NCT01963260

Last Updated: 2019-03-15

Results Overview

An AE is defined as any unfavorable and unintended medical occurrence in a clinical investigation participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment.

Recruitment status

COMPLETED

Study phase

PHASE1

Target enrollment

50 participants

Primary outcome timeframe

Up to 84 days

Results posted on

2019-03-15

Participant Flow

Amendment 3 specified a re-enrollment procedure for eligible participants in Part 2 to participate in more than one dosing panel.

2 participants that completed Part 2 10 mg/kg were re-enrolled in Part 2 100 mg/kg \& dosed. Both participants completed Part 2 100 mg/kg. 1 participant originally assigned to Part 2 30 mg/kg received placebo in error \& is included in Part 2 Placebo.

Participant milestones

Participant milestones
Measure	Part 1: MK-8723 1 mg/kg in Healthy Participants MK-8723 1 mg/kg administered as a single IV infusion to healthy participants in Part 1.	Part 1: MK-8723 3 mg/kg in Healthy Participants MK-8723 3 mg/kg administered as a single IV infusion to healthy participants in Part 1.	Part 1: MK-8723 10 mg/kg in Healthy Participants MK-8723 10 mg/kg administered as a single IV infusion to healthy participants in Part 1.	Part 1: MK-8723 30 mg/kg in Healthy Participants MK-8723 30 mg/kg administered as a single IV infusion to healthy participants in Part 1.	Part 1: MK-8723 100 mg/kg in Healthy Participants MK-8723 100 mg/kg administered as a single IV infusion to healthy participants in Part 1.	Part 1: Matching Placebo to MK-8723 Matching placebo to MK-8723 administered as a single IV infusion to healthy participants in Part 1.	Part 2: MK-8723 10 mg/kg in ITP Participants MK-8723 10 mg/kg administered as a single IV infusion to participants with immune thrombocytopenia purpura (ITP) in Part 2. 2 participants were subsequently enrolled in Part 2 MK-8723 100 mg/kg.	Part 2: MK-8723 30 mg/kg in ITP Participants MK-8723 30 mg/kg administered as a single IV infusion to participants with ITP in Part 2.	Part 2: MK-8723 100 mg/kg in ITP Participants MK-8723 100 mg/kg administered as a single IV infusion to participants with ITP in Part 2. 2 participants with ITP from Part 2 MK-8723 10 mg/kg were re-enrolled into Part 2 100 mg/kg and dosed (not shown).	Part 2: Matching Placebo to MK-8723 Matching placebo to MK-8723 administered as a single IV infusion to participants with ITP in Part 2.
Overall Study STARTED	6	6	6	6	6	10	3	2	1	4
Overall Study Treated	6	6	6	6	6	10	3	2	1	4
Overall Study COMPLETED	4	6	6	5	4	10	3	2	1	4
Overall Study NOT COMPLETED	2	0	0	1	2	0	0	0	0	0

Reasons for withdrawal

Reasons for withdrawal
Measure	Part 1: MK-8723 1 mg/kg in Healthy Participants MK-8723 1 mg/kg administered as a single IV infusion to healthy participants in Part 1.	Part 1: MK-8723 3 mg/kg in Healthy Participants MK-8723 3 mg/kg administered as a single IV infusion to healthy participants in Part 1.	Part 1: MK-8723 10 mg/kg in Healthy Participants MK-8723 10 mg/kg administered as a single IV infusion to healthy participants in Part 1.	Part 1: MK-8723 30 mg/kg in Healthy Participants MK-8723 30 mg/kg administered as a single IV infusion to healthy participants in Part 1.	Part 1: MK-8723 100 mg/kg in Healthy Participants MK-8723 100 mg/kg administered as a single IV infusion to healthy participants in Part 1.	Part 1: Matching Placebo to MK-8723 Matching placebo to MK-8723 administered as a single IV infusion to healthy participants in Part 1.	Part 2: MK-8723 10 mg/kg in ITP Participants MK-8723 10 mg/kg administered as a single IV infusion to participants with immune thrombocytopenia purpura (ITP) in Part 2. 2 participants were subsequently enrolled in Part 2 MK-8723 100 mg/kg.	Part 2: MK-8723 30 mg/kg in ITP Participants MK-8723 30 mg/kg administered as a single IV infusion to participants with ITP in Part 2.	Part 2: MK-8723 100 mg/kg in ITP Participants MK-8723 100 mg/kg administered as a single IV infusion to participants with ITP in Part 2. 2 participants with ITP from Part 2 MK-8723 10 mg/kg were re-enrolled into Part 2 100 mg/kg and dosed (not shown).	Part 2: Matching Placebo to MK-8723 Matching placebo to MK-8723 administered as a single IV infusion to participants with ITP in Part 2.
Overall Study Withdrawal by Subject	2	0	0	1	2	0	0	0	0	0

Baseline Characteristics

Single Rising Dose Study of MK-8723 in Healthy Participants and Participants With Immune Thrombocytopenia Purpura (MK-8723-001)

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure	Part 1: MK-8723 1 mg/kg in Healthy Participants n=6 Participants MK-8723 1 mg/kg administered as a single IV infusion to healthy participants in Part 1.	Part 1: MK-8723 3 mg/kg in Healthy Participants n=6 Participants MK-8723 3 mg/kg administered as a single IV infusion to healthy participants in Part 1.	Part 1: MK-8723 10 mg/kg in Healthy Participants n=6 Participants MK-8723 10 mg/kg administered as a single IV infusion to healthy participants in Part 1.	Part 1: MK-8723 30 mg/kg in Healthy Participants n=6 Participants MK-8723 30 mg/kg administered as a single IV infusion to healthy participants in Part 1.	Part 1: MK-8723 100 mg/kg in Healthy Participants n=6 Participants MK-8723 100 mg/kg administered as a single IV infusion to healthy participants in Part 1.	Part 1: Matching Placebo to MK-8723 n=10 Participants Matching placebo to MK-8723 administered as a single IV infusion to healthy participants in Part 1.	Part 2: MK-8723 10 mg/kg in ITP Participants n=3 Participants MK-8723 10 mg/kg administered as a single IV infusion to participants with ITP in Part 2. 2 participants subsequently enrolled in Part 2 MK-8723 100 mg/kg.	Part 2: MK-8723 30 mg/kg in ITP Participants n=2 Participants MK-8723 30 mg/kg administered as a single IV infusion to participants with ITP in Part 2.	Part 2: MK-8723 100 mg/kg in ITP Participants n=3 Participants MK-8723 100 mg/kg administered as a single IV infusion to participants with ITP in Part 2. This group includes 2 participants that re-enrolled from Part 2 MK-8723 10 mg/kg.	Part 2: Matching Placebo to MK-8723 n=4 Participants Matching placebo to MK-8723 administered as a single IV infusion to participants with ITP in Part 2.	Total n=52 Participants Total of all reporting groups
Age, Continuous	25.7 Years STANDARD_DEVIATION 2.7 • n=5 Participants	32.7 Years STANDARD_DEVIATION 13.0 • n=7 Participants	31.0 Years STANDARD_DEVIATION 12.2 • n=5 Participants	25.7 Years STANDARD_DEVIATION 4.2 • n=4 Participants	32.7 Years STANDARD_DEVIATION 10.5 • n=21 Participants	30.1 Years STANDARD_DEVIATION 9.5 • n=10 Participants	38.7 Years STANDARD_DEVIATION 22.3 • n=115 Participants	53.0 Years STANDARD_DEVIATION 4.2 • n=6 Participants	38.3 Years STANDARD_DEVIATION 22.7 • n=6 Participants	50.3 Years STANDARD_DEVIATION 13.5 • n=64 Participants	33.2 Years STANDARD_DEVIATION 13.0 • n=17 Participants
Age, Customized Between 18 and 65 years	6 Participants n=5 Participants	6 Participants n=7 Participants	6 Participants n=5 Participants	6 Participants n=4 Participants	6 Participants n=21 Participants	10 Participants n=10 Participants	3 Participants n=115 Participants	2 Participants n=6 Participants	3 Participants n=6 Participants	3 Participants n=64 Participants	51 Participants n=17 Participants
Age, Customized >=65 years	0 Participants n=5 Participants	0 Participants n=7 Participants	0 Participants n=5 Participants	0 Participants n=4 Participants	0 Participants n=21 Participants	0 Participants n=10 Participants	0 Participants n=115 Participants	0 Participants n=6 Participants	0 Participants n=6 Participants	1 Participants n=64 Participants	1 Participants n=17 Participants
Sex: Female, Male Female	0 Participants n=5 Participants	0 Participants n=7 Participants	1 Participants n=5 Participants	0 Participants n=4 Participants	0 Participants n=21 Participants	1 Participants n=10 Participants	1 Participants n=115 Participants	2 Participants n=6 Participants	2 Participants n=6 Participants	3 Participants n=64 Participants	10 Participants n=17 Participants
Sex: Female, Male Male	6 Participants n=5 Participants	6 Participants n=7 Participants	5 Participants n=5 Participants	6 Participants n=4 Participants	6 Participants n=21 Participants	9 Participants n=10 Participants	2 Participants n=115 Participants	0 Participants n=6 Participants	1 Participants n=6 Participants	1 Participants n=64 Participants	42 Participants n=17 Participants

PRIMARY outcome

Timeframe: Up to 84 days

Population: The All Participants as Treated (APaT) population consisting of all participants who received at least one dose of study drug was used for the safety analysis.

Outcome measures

Outcome measures
Measure	Part 1: MK-8723 1 mg/kg in Healthy Participants n=6 Participants MK-8723 1 mg/kg administered as a single IV infusion to healthy participants in Part 1.	Part 1: MK-8723 3 mg/kg in Healthy Participants n=6 Participants MK-8723 3 mg/kg administered as a single IV infusion to healthy participants in Part 1.	Part 1: MK-8723 10 mg/kg in Healthy Participants n=6 Participants MK-8723 10 mg/kg administered as a single IV infusion to healthy participants in Part 1.	Part 1: MK-8723 30 mg/kg in Healthy Participants n=6 Participants MK-8723 30 mg/kg administered as a single IV infusion to healthy participants in Part 1.	Part 1: MK-8723 100 mg/kg in Healthy Participants n=6 Participants MK-8723 100 mg/kg administered as a single IV infusion to healthy participants in Part 1.	Part 1: Matching Placebo to MK-8723 n=10 Participants Matching placebo to MK-8723 administered as a single IV infusion to healthy participants in Part 1.	Part 2: MK-8723 10 mg/kg in ITP Participants n=3 Participants MK-8723 10 mg/kg administered as a single IV infusion to participants with ITP in Part 2. 2 participants subsequently enrolled in Part 2 MK-8723 100 mg/kg.	Part 2: MK-8723 30 mg/kg in ITP Participants n=2 Participants MK-8723 30 mg/kg administered as a single IV infusion to participants with ITP in Part 2.	Part 2: MK-8723 100 mg/kg in ITP Participants n=3 Participants MK-8723 100 mg/kg administered as a single IV infusion to participants with ITP in Part 2. This group includes 2 participants that re-enrolled from Part 2 MK-8723 10 mg/kg.	Part 2: Matching Placebo to MK-8723 n=4 Participants Matching placebo to MK-8723 administered as a single IV infusion to participants with ITP in Part 2.
Number of Participants Experiencing an Adverse Event	2 Participants	2 Participants	4 Participants	1 Participants	4 Participants	6 Participants	1 Participants	2 Participants	2 Participants	2 Participants

PRIMARY outcome

Timeframe: Up to 84 Days

Population: The APaT population consisting of all participants who received at least one dose of study drug was used for the safety analysis.

Outcome measures

Outcome measures
Measure	Part 1: MK-8723 1 mg/kg in Healthy Participants n=6 Participants MK-8723 1 mg/kg administered as a single IV infusion to healthy participants in Part 1.	Part 1: MK-8723 3 mg/kg in Healthy Participants n=6 Participants MK-8723 3 mg/kg administered as a single IV infusion to healthy participants in Part 1.	Part 1: MK-8723 10 mg/kg in Healthy Participants n=6 Participants MK-8723 10 mg/kg administered as a single IV infusion to healthy participants in Part 1.	Part 1: MK-8723 30 mg/kg in Healthy Participants n=6 Participants MK-8723 30 mg/kg administered as a single IV infusion to healthy participants in Part 1.	Part 1: MK-8723 100 mg/kg in Healthy Participants n=6 Participants MK-8723 100 mg/kg administered as a single IV infusion to healthy participants in Part 1.	Part 1: Matching Placebo to MK-8723 n=10 Participants Matching placebo to MK-8723 administered as a single IV infusion to healthy participants in Part 1.	Part 2: MK-8723 10 mg/kg in ITP Participants n=3 Participants MK-8723 10 mg/kg administered as a single IV infusion to participants with ITP in Part 2. 2 participants subsequently enrolled in Part 2 MK-8723 100 mg/kg.	Part 2: MK-8723 30 mg/kg in ITP Participants n=2 Participants MK-8723 30 mg/kg administered as a single IV infusion to participants with ITP in Part 2.	Part 2: MK-8723 100 mg/kg in ITP Participants n=3 Participants MK-8723 100 mg/kg administered as a single IV infusion to participants with ITP in Part 2. This group includes 2 participants that re-enrolled from Part 2 MK-8723 10 mg/kg.	Part 2: Matching Placebo to MK-8723 n=4 Participants Matching placebo to MK-8723 administered as a single IV infusion to participants with ITP in Part 2.
Number of Participants Discontinuing Study Due to an Adverse Event (AE)	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants

PRIMARY outcome

Timeframe: Up to Day 14

Population: The per protocol population consisting of all participants in compliance with the protocol (e.g., availability of measurements, absence of major protocol violations) was used for the pharmacodynamic (platelet response) analysis.

In participants with ITP, platelet response is a rapid, sensitive, and highly qualitative measure of response to anti-inflammatory therapy. A positive platelet response was defined as: 1) A doubling of platelet counts at the time point of maximum response (through Day 14) as compared to Day 0 AND an increase to an absolute level of ≥50,000/μL in participants with a baseline platelet count of \<50,000/μL, OR 2) A 50% increase in the platelet count at the time point of maximum response (through Day 14) as compared to Day 0 in participants with a baseline platelet count of ≥50,000/μL. The analysis was specified only for participants with ITP (Part 2) that received treatment with MK-8723 or matching placebo.

Outcome measures

Outcome measures
Measure	Part 1: MK-8723 1 mg/kg in Healthy Participants n=3 Participants MK-8723 1 mg/kg administered as a single IV infusion to healthy participants in Part 1.	Part 1: MK-8723 3 mg/kg in Healthy Participants n=2 Participants MK-8723 3 mg/kg administered as a single IV infusion to healthy participants in Part 1.	Part 1: MK-8723 10 mg/kg in Healthy Participants n=3 Participants MK-8723 10 mg/kg administered as a single IV infusion to healthy participants in Part 1.	Part 1: MK-8723 30 mg/kg in Healthy Participants n=4 Participants MK-8723 30 mg/kg administered as a single IV infusion to healthy participants in Part 1.	Part 1: MK-8723 100 mg/kg in Healthy Participants MK-8723 100 mg/kg administered as a single IV infusion to healthy participants in Part 1.	Part 1: Matching Placebo to MK-8723 Matching placebo to MK-8723 administered as a single IV infusion to healthy participants in Part 1.	Part 2: MK-8723 10 mg/kg in ITP Participants MK-8723 10 mg/kg administered as a single IV infusion to participants with ITP in Part 2. 2 participants subsequently enrolled in Part 2 MK-8723 100 mg/kg.	Part 2: MK-8723 30 mg/kg in ITP Participants MK-8723 30 mg/kg administered as a single IV infusion to participants with ITP in Part 2.	Part 2: MK-8723 100 mg/kg in ITP Participants MK-8723 100 mg/kg administered as a single IV infusion to participants with ITP in Part 2. This group includes 2 participants that re-enrolled from Part 2 MK-8723 10 mg/kg.	Part 2: Matching Placebo to MK-8723 Matching placebo to MK-8723 administered as a single IV infusion to participants with ITP in Part 2.
Number of Participants With a Positive Platelet Response to MK-8723	0 Participants	0 Participants	0 Participants	0 Participants	—	—	—	—	—	—

SECONDARY outcome

Timeframe: All dose groups: Predose and 4 (end of infusion), 6, 12, 24 hrs postdose and Days 3, 4, 5, 7, 10, 14, 21, 28; 30 mg/kg and 100 mg/kg dose groups: Days 43, 56, 71, 84

AUC0-∞ is a measure of total body exposure to drug. Serum samples for determination of AUC0-∞ were collected at pre-specified time-points.

Outcome measures

Outcome measures
Measure	Part 1: MK-8723 1 mg/kg in Healthy Participants n=6 Participants MK-8723 1 mg/kg administered as a single IV infusion to healthy participants in Part 1.	Part 1: MK-8723 3 mg/kg in Healthy Participants n=6 Participants MK-8723 3 mg/kg administered as a single IV infusion to healthy participants in Part 1.	Part 1: MK-8723 10 mg/kg in Healthy Participants n=6 Participants MK-8723 10 mg/kg administered as a single IV infusion to healthy participants in Part 1.	Part 1: MK-8723 30 mg/kg in Healthy Participants n=6 Participants MK-8723 30 mg/kg administered as a single IV infusion to healthy participants in Part 1.	Part 1: MK-8723 100 mg/kg in Healthy Participants n=6 Participants MK-8723 100 mg/kg administered as a single IV infusion to healthy participants in Part 1.	Part 1: Matching Placebo to MK-8723 n=3 Participants Matching placebo to MK-8723 administered as a single IV infusion to healthy participants in Part 1.	Part 2: MK-8723 10 mg/kg in ITP Participants n=2 Participants MK-8723 10 mg/kg administered as a single IV infusion to participants with ITP in Part 2. 2 participants subsequently enrolled in Part 2 MK-8723 100 mg/kg.	Part 2: MK-8723 30 mg/kg in ITP Participants n=3 Participants MK-8723 30 mg/kg administered as a single IV infusion to participants with ITP in Part 2.	Part 2: MK-8723 100 mg/kg in ITP Participants MK-8723 100 mg/kg administered as a single IV infusion to participants with ITP in Part 2. This group includes 2 participants that re-enrolled from Part 2 MK-8723 10 mg/kg.	Part 2: Matching Placebo to MK-8723 Matching placebo to MK-8723 administered as a single IV infusion to participants with ITP in Part 2.
Area Under the Concentration-time Curve of MK-8723 From Time 0 to Infinity (AUC0-∞) Among Healthy Participants and Participants With ITP	4830 hr*μg/mL Geometric Coefficient of Variation 22.1	22300 hr*μg/mL Geometric Coefficient of Variation 21.9	65800 hr*μg/mL Geometric Coefficient of Variation 13.4	186000 hr*μg/mL Geometric Coefficient of Variation 7.28	711000 hr*μg/mL Geometric Coefficient of Variation 50.5	66200 hr*μg/mL Geometric Coefficient of Variation 57.9	203000 hr*μg/mL Geometric Coefficient of Variation 22.6	668000 hr*μg/mL Geometric Coefficient of Variation 19.4	—	—

SECONDARY outcome

Timeframe: All dose groups: Predose and 4 (end of infusion), 6, 12, 24 hrs postdose and Days 3, 4, 5, 7, 10, 14, 21, 28; 30 mg/kg and 100 mg/kg dose groups: Days 43, 56, 71, 84

Serum samples for determination of Cmax were collected at pre-specified time-points.

Outcome measures

Outcome measures
Measure	Part 1: MK-8723 1 mg/kg in Healthy Participants n=6 Participants MK-8723 1 mg/kg administered as a single IV infusion to healthy participants in Part 1.	Part 1: MK-8723 3 mg/kg in Healthy Participants n=6 Participants MK-8723 3 mg/kg administered as a single IV infusion to healthy participants in Part 1.	Part 1: MK-8723 10 mg/kg in Healthy Participants n=6 Participants MK-8723 10 mg/kg administered as a single IV infusion to healthy participants in Part 1.	Part 1: MK-8723 30 mg/kg in Healthy Participants n=6 Participants MK-8723 30 mg/kg administered as a single IV infusion to healthy participants in Part 1.	Part 1: MK-8723 100 mg/kg in Healthy Participants n=6 Participants MK-8723 100 mg/kg administered as a single IV infusion to healthy participants in Part 1.	Part 1: Matching Placebo to MK-8723 n=3 Participants Matching placebo to MK-8723 administered as a single IV infusion to healthy participants in Part 1.	Part 2: MK-8723 10 mg/kg in ITP Participants n=2 Participants MK-8723 10 mg/kg administered as a single IV infusion to participants with ITP in Part 2. 2 participants subsequently enrolled in Part 2 MK-8723 100 mg/kg.	Part 2: MK-8723 30 mg/kg in ITP Participants n=3 Participants MK-8723 30 mg/kg administered as a single IV infusion to participants with ITP in Part 2.	Part 2: MK-8723 100 mg/kg in ITP Participants MK-8723 100 mg/kg administered as a single IV infusion to participants with ITP in Part 2. This group includes 2 participants that re-enrolled from Part 2 MK-8723 10 mg/kg.	Part 2: Matching Placebo to MK-8723 Matching placebo to MK-8723 administered as a single IV infusion to participants with ITP in Part 2.
Maximum Concentration (Cmax) of MK-8723 Among Healthy Participants and Participants With ITP	18.7 μg/mL Geometric Coefficient of Variation 11.4	72.3 μg/mL Geometric Coefficient of Variation 8.53	225 μg/mL Geometric Coefficient of Variation 15.5	844 μg/mL Geometric Coefficient of Variation 12.2	2160 μg/mL Geometric Coefficient of Variation 23.9	195 μg/mL Geometric Coefficient of Variation 11.7	741 μg/mL Geometric Coefficient of Variation 24.8	2450 μg/mL Geometric Coefficient of Variation 8.63	—	—

Deaths: 0 deaths

Serious adverse events

Adverse event data not reported

Other adverse events

Other adverse events
Measure	Part 1: MK-8723 1 mg/kg in Healthy Participants n=6 participants at risk MK-8723 1 mg/kg administered as a single IV infusion to healthy participants in Part 1.	Part 1: MK-8723 3 mg/kg in Healthy Participants n=6 participants at risk MK-8723 3 mg/kg administered as a single IV infusion to healthy participants in Part 1.	Part 1: MK-8723 10 mg/kg in Healthy Participants n=6 participants at risk MK-8723 10 mg/kg administered as a single IV infusion to healthy participants in Part 1.	Part 1: MK-8723 30 mg/kg in Healthy Participants n=6 participants at risk MK-8723 30 mg/kg administered as a single IV infusion to healthy participants in Part 1.	Part 1: MK-8723 100 mg/kg in Healthy Participants n=6 participants at risk MK-8723 100 mg/kg administered as a single IV infusion to healthy participants in Part 1.	Part 1: Matching Placebo to MK-8723 n=10 participants at risk Matching placebo to MK-8723 administered as a single IV infusion to healthy participants in Part 1.	Part 2: MK-8723 10 mg/kg in ITP Participants n=3 participants at risk MK-8723 10 mg/kg administered as a single IV infusion to participants with ITP in Part 2. 2 participants subsequently enrolled in Part 2 MK-8723 100 mg/kg.	Part 2: MK-8723 30 mg/kg in ITP Participants n=2 participants at risk MK-8723 30 mg/kg administered as a single IV infusion to participants with ITP in Part 2.	Part 2: MK-8723 100 mg/kg in ITP Participants n=3 participants at risk MK-8723 100 mg/kg administered as a single IV infusion to participants with ITP in Part 2. This group includes 2 participants that re-enrolled from Part 2 MK-8723 10 mg/kg.	Part 2: Matching Placebo to MK-8723 n=4 participants at risk Matching placebo to MK-8723 administered as a single IV infusion to participants with ITP in Part 2.
Gastrointestinal disorders Abdominal distension	0.00% 0/6 • Up to 84 days The APaT population consisting of all participants who received at least one dose of study drug was used for the safety analysis. AEs are presented according to the actual treatment administered (i.e., as treated). 2 participants that completed Part 2 MK-8723 10 mg/kg were re-enrolled in Part 2 MK-8723 100 mg/kg \& dosed per protocol procedure.	0.00% 0/6 • Up to 84 days The APaT population consisting of all participants who received at least one dose of study drug was used for the safety analysis. AEs are presented according to the actual treatment administered (i.e., as treated). 2 participants that completed Part 2 MK-8723 10 mg/kg were re-enrolled in Part 2 MK-8723 100 mg/kg \& dosed per protocol procedure.	16.7% 1/6 • Number of events 1 • Up to 84 days The APaT population consisting of all participants who received at least one dose of study drug was used for the safety analysis. AEs are presented according to the actual treatment administered (i.e., as treated). 2 participants that completed Part 2 MK-8723 10 mg/kg were re-enrolled in Part 2 MK-8723 100 mg/kg \& dosed per protocol procedure.	0.00% 0/6 • Up to 84 days The APaT population consisting of all participants who received at least one dose of study drug was used for the safety analysis. AEs are presented according to the actual treatment administered (i.e., as treated). 2 participants that completed Part 2 MK-8723 10 mg/kg were re-enrolled in Part 2 MK-8723 100 mg/kg \& dosed per protocol procedure.	0.00% 0/6 • Up to 84 days The APaT population consisting of all participants who received at least one dose of study drug was used for the safety analysis. AEs are presented according to the actual treatment administered (i.e., as treated). 2 participants that completed Part 2 MK-8723 10 mg/kg were re-enrolled in Part 2 MK-8723 100 mg/kg \& dosed per protocol procedure.	0.00% 0/10 • Up to 84 days The APaT population consisting of all participants who received at least one dose of study drug was used for the safety analysis. AEs are presented according to the actual treatment administered (i.e., as treated). 2 participants that completed Part 2 MK-8723 10 mg/kg were re-enrolled in Part 2 MK-8723 100 mg/kg \& dosed per protocol procedure.	0.00% 0/3 • Up to 84 days The APaT population consisting of all participants who received at least one dose of study drug was used for the safety analysis. AEs are presented according to the actual treatment administered (i.e., as treated). 2 participants that completed Part 2 MK-8723 10 mg/kg were re-enrolled in Part 2 MK-8723 100 mg/kg \& dosed per protocol procedure.	0.00% 0/2 • Up to 84 days The APaT population consisting of all participants who received at least one dose of study drug was used for the safety analysis. AEs are presented according to the actual treatment administered (i.e., as treated). 2 participants that completed Part 2 MK-8723 10 mg/kg were re-enrolled in Part 2 MK-8723 100 mg/kg \& dosed per protocol procedure.	0.00% 0/3 • Up to 84 days The APaT population consisting of all participants who received at least one dose of study drug was used for the safety analysis. AEs are presented according to the actual treatment administered (i.e., as treated). 2 participants that completed Part 2 MK-8723 10 mg/kg were re-enrolled in Part 2 MK-8723 100 mg/kg \& dosed per protocol procedure.	0.00% 0/4 • Up to 84 days The APaT population consisting of all participants who received at least one dose of study drug was used for the safety analysis. AEs are presented according to the actual treatment administered (i.e., as treated). 2 participants that completed Part 2 MK-8723 10 mg/kg were re-enrolled in Part 2 MK-8723 100 mg/kg \& dosed per protocol procedure.
Gastrointestinal disorders Diarrhoea	0.00% 0/6 • Up to 84 days The APaT population consisting of all participants who received at least one dose of study drug was used for the safety analysis. AEs are presented according to the actual treatment administered (i.e., as treated). 2 participants that completed Part 2 MK-8723 10 mg/kg were re-enrolled in Part 2 MK-8723 100 mg/kg \& dosed per protocol procedure.	0.00% 0/6 • Up to 84 days The APaT population consisting of all participants who received at least one dose of study drug was used for the safety analysis. AEs are presented according to the actual treatment administered (i.e., as treated). 2 participants that completed Part 2 MK-8723 10 mg/kg were re-enrolled in Part 2 MK-8723 100 mg/kg \& dosed per protocol procedure.	0.00% 0/6 • Up to 84 days The APaT population consisting of all participants who received at least one dose of study drug was used for the safety analysis. AEs are presented according to the actual treatment administered (i.e., as treated). 2 participants that completed Part 2 MK-8723 10 mg/kg were re-enrolled in Part 2 MK-8723 100 mg/kg \& dosed per protocol procedure.	0.00% 0/6 • Up to 84 days The APaT population consisting of all participants who received at least one dose of study drug was used for the safety analysis. AEs are presented according to the actual treatment administered (i.e., as treated). 2 participants that completed Part 2 MK-8723 10 mg/kg were re-enrolled in Part 2 MK-8723 100 mg/kg \& dosed per protocol procedure.	0.00% 0/6 • Up to 84 days The APaT population consisting of all participants who received at least one dose of study drug was used for the safety analysis. AEs are presented according to the actual treatment administered (i.e., as treated). 2 participants that completed Part 2 MK-8723 10 mg/kg were re-enrolled in Part 2 MK-8723 100 mg/kg \& dosed per protocol procedure.	0.00% 0/10 • Up to 84 days The APaT population consisting of all participants who received at least one dose of study drug was used for the safety analysis. AEs are presented according to the actual treatment administered (i.e., as treated). 2 participants that completed Part 2 MK-8723 10 mg/kg were re-enrolled in Part 2 MK-8723 100 mg/kg \& dosed per protocol procedure.	0.00% 0/3 • Up to 84 days The APaT population consisting of all participants who received at least one dose of study drug was used for the safety analysis. AEs are presented according to the actual treatment administered (i.e., as treated). 2 participants that completed Part 2 MK-8723 10 mg/kg were re-enrolled in Part 2 MK-8723 100 mg/kg \& dosed per protocol procedure.	50.0% 1/2 • Number of events 1 • Up to 84 days The APaT population consisting of all participants who received at least one dose of study drug was used for the safety analysis. AEs are presented according to the actual treatment administered (i.e., as treated). 2 participants that completed Part 2 MK-8723 10 mg/kg were re-enrolled in Part 2 MK-8723 100 mg/kg \& dosed per protocol procedure.	0.00% 0/3 • Up to 84 days The APaT population consisting of all participants who received at least one dose of study drug was used for the safety analysis. AEs are presented according to the actual treatment administered (i.e., as treated). 2 participants that completed Part 2 MK-8723 10 mg/kg were re-enrolled in Part 2 MK-8723 100 mg/kg \& dosed per protocol procedure.	0.00% 0/4 • Up to 84 days The APaT population consisting of all participants who received at least one dose of study drug was used for the safety analysis. AEs are presented according to the actual treatment administered (i.e., as treated). 2 participants that completed Part 2 MK-8723 10 mg/kg were re-enrolled in Part 2 MK-8723 100 mg/kg \& dosed per protocol procedure.
Gastrointestinal disorders Frequent bowel movements	0.00% 0/6 • Up to 84 days The APaT population consisting of all participants who received at least one dose of study drug was used for the safety analysis. AEs are presented according to the actual treatment administered (i.e., as treated). 2 participants that completed Part 2 MK-8723 10 mg/kg were re-enrolled in Part 2 MK-8723 100 mg/kg \& dosed per protocol procedure.	0.00% 0/6 • Up to 84 days The APaT population consisting of all participants who received at least one dose of study drug was used for the safety analysis. AEs are presented according to the actual treatment administered (i.e., as treated). 2 participants that completed Part 2 MK-8723 10 mg/kg were re-enrolled in Part 2 MK-8723 100 mg/kg \& dosed per protocol procedure.	0.00% 0/6 • Up to 84 days The APaT population consisting of all participants who received at least one dose of study drug was used for the safety analysis. AEs are presented according to the actual treatment administered (i.e., as treated). 2 participants that completed Part 2 MK-8723 10 mg/kg were re-enrolled in Part 2 MK-8723 100 mg/kg \& dosed per protocol procedure.	0.00% 0/6 • Up to 84 days The APaT population consisting of all participants who received at least one dose of study drug was used for the safety analysis. AEs are presented according to the actual treatment administered (i.e., as treated). 2 participants that completed Part 2 MK-8723 10 mg/kg were re-enrolled in Part 2 MK-8723 100 mg/kg \& dosed per protocol procedure.	0.00% 0/6 • Up to 84 days The APaT population consisting of all participants who received at least one dose of study drug was used for the safety analysis. AEs are presented according to the actual treatment administered (i.e., as treated). 2 participants that completed Part 2 MK-8723 10 mg/kg were re-enrolled in Part 2 MK-8723 100 mg/kg \& dosed per protocol procedure.	10.0% 1/10 • Number of events 1 • Up to 84 days The APaT population consisting of all participants who received at least one dose of study drug was used for the safety analysis. AEs are presented according to the actual treatment administered (i.e., as treated). 2 participants that completed Part 2 MK-8723 10 mg/kg were re-enrolled in Part 2 MK-8723 100 mg/kg \& dosed per protocol procedure.	0.00% 0/3 • Up to 84 days The APaT population consisting of all participants who received at least one dose of study drug was used for the safety analysis. AEs are presented according to the actual treatment administered (i.e., as treated). 2 participants that completed Part 2 MK-8723 10 mg/kg were re-enrolled in Part 2 MK-8723 100 mg/kg \& dosed per protocol procedure.	0.00% 0/2 • Up to 84 days The APaT population consisting of all participants who received at least one dose of study drug was used for the safety analysis. AEs are presented according to the actual treatment administered (i.e., as treated). 2 participants that completed Part 2 MK-8723 10 mg/kg were re-enrolled in Part 2 MK-8723 100 mg/kg \& dosed per protocol procedure.	0.00% 0/3 • Up to 84 days The APaT population consisting of all participants who received at least one dose of study drug was used for the safety analysis. AEs are presented according to the actual treatment administered (i.e., as treated). 2 participants that completed Part 2 MK-8723 10 mg/kg were re-enrolled in Part 2 MK-8723 100 mg/kg \& dosed per protocol procedure.	0.00% 0/4 • Up to 84 days The APaT population consisting of all participants who received at least one dose of study drug was used for the safety analysis. AEs are presented according to the actual treatment administered (i.e., as treated). 2 participants that completed Part 2 MK-8723 10 mg/kg were re-enrolled in Part 2 MK-8723 100 mg/kg \& dosed per protocol procedure.
Gastrointestinal disorders Toothache	0.00% 0/6 • Up to 84 days The APaT population consisting of all participants who received at least one dose of study drug was used for the safety analysis. AEs are presented according to the actual treatment administered (i.e., as treated). 2 participants that completed Part 2 MK-8723 10 mg/kg were re-enrolled in Part 2 MK-8723 100 mg/kg \& dosed per protocol procedure.	16.7% 1/6 • Number of events 1 • Up to 84 days The APaT population consisting of all participants who received at least one dose of study drug was used for the safety analysis. AEs are presented according to the actual treatment administered (i.e., as treated). 2 participants that completed Part 2 MK-8723 10 mg/kg were re-enrolled in Part 2 MK-8723 100 mg/kg \& dosed per protocol procedure.	0.00% 0/6 • Up to 84 days The APaT population consisting of all participants who received at least one dose of study drug was used for the safety analysis. AEs are presented according to the actual treatment administered (i.e., as treated). 2 participants that completed Part 2 MK-8723 10 mg/kg were re-enrolled in Part 2 MK-8723 100 mg/kg \& dosed per protocol procedure.	0.00% 0/6 • Up to 84 days The APaT population consisting of all participants who received at least one dose of study drug was used for the safety analysis. AEs are presented according to the actual treatment administered (i.e., as treated). 2 participants that completed Part 2 MK-8723 10 mg/kg were re-enrolled in Part 2 MK-8723 100 mg/kg \& dosed per protocol procedure.	0.00% 0/6 • Up to 84 days The APaT population consisting of all participants who received at least one dose of study drug was used for the safety analysis. AEs are presented according to the actual treatment administered (i.e., as treated). 2 participants that completed Part 2 MK-8723 10 mg/kg were re-enrolled in Part 2 MK-8723 100 mg/kg \& dosed per protocol procedure.	0.00% 0/10 • Up to 84 days The APaT population consisting of all participants who received at least one dose of study drug was used for the safety analysis. AEs are presented according to the actual treatment administered (i.e., as treated). 2 participants that completed Part 2 MK-8723 10 mg/kg were re-enrolled in Part 2 MK-8723 100 mg/kg \& dosed per protocol procedure.	0.00% 0/3 • Up to 84 days The APaT population consisting of all participants who received at least one dose of study drug was used for the safety analysis. AEs are presented according to the actual treatment administered (i.e., as treated). 2 participants that completed Part 2 MK-8723 10 mg/kg were re-enrolled in Part 2 MK-8723 100 mg/kg \& dosed per protocol procedure.	0.00% 0/2 • Up to 84 days The APaT population consisting of all participants who received at least one dose of study drug was used for the safety analysis. AEs are presented according to the actual treatment administered (i.e., as treated). 2 participants that completed Part 2 MK-8723 10 mg/kg were re-enrolled in Part 2 MK-8723 100 mg/kg \& dosed per protocol procedure.	0.00% 0/3 • Up to 84 days The APaT population consisting of all participants who received at least one dose of study drug was used for the safety analysis. AEs are presented according to the actual treatment administered (i.e., as treated). 2 participants that completed Part 2 MK-8723 10 mg/kg were re-enrolled in Part 2 MK-8723 100 mg/kg \& dosed per protocol procedure.	0.00% 0/4 • Up to 84 days The APaT population consisting of all participants who received at least one dose of study drug was used for the safety analysis. AEs are presented according to the actual treatment administered (i.e., as treated). 2 participants that completed Part 2 MK-8723 10 mg/kg were re-enrolled in Part 2 MK-8723 100 mg/kg \& dosed per protocol procedure.
General disorders Fatigue	0.00% 0/6 • Up to 84 days The APaT population consisting of all participants who received at least one dose of study drug was used for the safety analysis. AEs are presented according to the actual treatment administered (i.e., as treated). 2 participants that completed Part 2 MK-8723 10 mg/kg were re-enrolled in Part 2 MK-8723 100 mg/kg \& dosed per protocol procedure.	0.00% 0/6 • Up to 84 days The APaT population consisting of all participants who received at least one dose of study drug was used for the safety analysis. AEs are presented according to the actual treatment administered (i.e., as treated). 2 participants that completed Part 2 MK-8723 10 mg/kg were re-enrolled in Part 2 MK-8723 100 mg/kg \& dosed per protocol procedure.	0.00% 0/6 • Up to 84 days The APaT population consisting of all participants who received at least one dose of study drug was used for the safety analysis. AEs are presented according to the actual treatment administered (i.e., as treated). 2 participants that completed Part 2 MK-8723 10 mg/kg were re-enrolled in Part 2 MK-8723 100 mg/kg \& dosed per protocol procedure.	0.00% 0/6 • Up to 84 days The APaT population consisting of all participants who received at least one dose of study drug was used for the safety analysis. AEs are presented according to the actual treatment administered (i.e., as treated). 2 participants that completed Part 2 MK-8723 10 mg/kg were re-enrolled in Part 2 MK-8723 100 mg/kg \& dosed per protocol procedure.	0.00% 0/6 • Up to 84 days The APaT population consisting of all participants who received at least one dose of study drug was used for the safety analysis. AEs are presented according to the actual treatment administered (i.e., as treated). 2 participants that completed Part 2 MK-8723 10 mg/kg were re-enrolled in Part 2 MK-8723 100 mg/kg \& dosed per protocol procedure.	0.00% 0/10 • Up to 84 days The APaT population consisting of all participants who received at least one dose of study drug was used for the safety analysis. AEs are presented according to the actual treatment administered (i.e., as treated). 2 participants that completed Part 2 MK-8723 10 mg/kg were re-enrolled in Part 2 MK-8723 100 mg/kg \& dosed per protocol procedure.	0.00% 0/3 • Up to 84 days The APaT population consisting of all participants who received at least one dose of study drug was used for the safety analysis. AEs are presented according to the actual treatment administered (i.e., as treated). 2 participants that completed Part 2 MK-8723 10 mg/kg were re-enrolled in Part 2 MK-8723 100 mg/kg \& dosed per protocol procedure.	0.00% 0/2 • Up to 84 days The APaT population consisting of all participants who received at least one dose of study drug was used for the safety analysis. AEs are presented according to the actual treatment administered (i.e., as treated). 2 participants that completed Part 2 MK-8723 10 mg/kg were re-enrolled in Part 2 MK-8723 100 mg/kg \& dosed per protocol procedure.	0.00% 0/3 • Up to 84 days The APaT population consisting of all participants who received at least one dose of study drug was used for the safety analysis. AEs are presented according to the actual treatment administered (i.e., as treated). 2 participants that completed Part 2 MK-8723 10 mg/kg were re-enrolled in Part 2 MK-8723 100 mg/kg \& dosed per protocol procedure.	25.0% 1/4 • Number of events 1 • Up to 84 days The APaT population consisting of all participants who received at least one dose of study drug was used for the safety analysis. AEs are presented according to the actual treatment administered (i.e., as treated). 2 participants that completed Part 2 MK-8723 10 mg/kg were re-enrolled in Part 2 MK-8723 100 mg/kg \& dosed per protocol procedure.
General disorders Feeling abnormal	0.00% 0/6 • Up to 84 days The APaT population consisting of all participants who received at least one dose of study drug was used for the safety analysis. AEs are presented according to the actual treatment administered (i.e., as treated). 2 participants that completed Part 2 MK-8723 10 mg/kg were re-enrolled in Part 2 MK-8723 100 mg/kg \& dosed per protocol procedure.	0.00% 0/6 • Up to 84 days The APaT population consisting of all participants who received at least one dose of study drug was used for the safety analysis. AEs are presented according to the actual treatment administered (i.e., as treated). 2 participants that completed Part 2 MK-8723 10 mg/kg were re-enrolled in Part 2 MK-8723 100 mg/kg \& dosed per protocol procedure.	0.00% 0/6 • Up to 84 days The APaT population consisting of all participants who received at least one dose of study drug was used for the safety analysis. AEs are presented according to the actual treatment administered (i.e., as treated). 2 participants that completed Part 2 MK-8723 10 mg/kg were re-enrolled in Part 2 MK-8723 100 mg/kg \& dosed per protocol procedure.	0.00% 0/6 • Up to 84 days The APaT population consisting of all participants who received at least one dose of study drug was used for the safety analysis. AEs are presented according to the actual treatment administered (i.e., as treated). 2 participants that completed Part 2 MK-8723 10 mg/kg were re-enrolled in Part 2 MK-8723 100 mg/kg \& dosed per protocol procedure.	0.00% 0/6 • Up to 84 days The APaT population consisting of all participants who received at least one dose of study drug was used for the safety analysis. AEs are presented according to the actual treatment administered (i.e., as treated). 2 participants that completed Part 2 MK-8723 10 mg/kg were re-enrolled in Part 2 MK-8723 100 mg/kg \& dosed per protocol procedure.	10.0% 1/10 • Number of events 1 • Up to 84 days The APaT population consisting of all participants who received at least one dose of study drug was used for the safety analysis. AEs are presented according to the actual treatment administered (i.e., as treated). 2 participants that completed Part 2 MK-8723 10 mg/kg were re-enrolled in Part 2 MK-8723 100 mg/kg \& dosed per protocol procedure.	0.00% 0/3 • Up to 84 days The APaT population consisting of all participants who received at least one dose of study drug was used for the safety analysis. AEs are presented according to the actual treatment administered (i.e., as treated). 2 participants that completed Part 2 MK-8723 10 mg/kg were re-enrolled in Part 2 MK-8723 100 mg/kg \& dosed per protocol procedure.	0.00% 0/2 • Up to 84 days The APaT population consisting of all participants who received at least one dose of study drug was used for the safety analysis. AEs are presented according to the actual treatment administered (i.e., as treated). 2 participants that completed Part 2 MK-8723 10 mg/kg were re-enrolled in Part 2 MK-8723 100 mg/kg \& dosed per protocol procedure.	0.00% 0/3 • Up to 84 days The APaT population consisting of all participants who received at least one dose of study drug was used for the safety analysis. AEs are presented according to the actual treatment administered (i.e., as treated). 2 participants that completed Part 2 MK-8723 10 mg/kg were re-enrolled in Part 2 MK-8723 100 mg/kg \& dosed per protocol procedure.	0.00% 0/4 • Up to 84 days The APaT population consisting of all participants who received at least one dose of study drug was used for the safety analysis. AEs are presented according to the actual treatment administered (i.e., as treated). 2 participants that completed Part 2 MK-8723 10 mg/kg were re-enrolled in Part 2 MK-8723 100 mg/kg \& dosed per protocol procedure.
General disorders Influenza like illness	0.00% 0/6 • Up to 84 days The APaT population consisting of all participants who received at least one dose of study drug was used for the safety analysis. AEs are presented according to the actual treatment administered (i.e., as treated). 2 participants that completed Part 2 MK-8723 10 mg/kg were re-enrolled in Part 2 MK-8723 100 mg/kg \& dosed per protocol procedure.	0.00% 0/6 • Up to 84 days The APaT population consisting of all participants who received at least one dose of study drug was used for the safety analysis. AEs are presented according to the actual treatment administered (i.e., as treated). 2 participants that completed Part 2 MK-8723 10 mg/kg were re-enrolled in Part 2 MK-8723 100 mg/kg \& dosed per protocol procedure.	0.00% 0/6 • Up to 84 days The APaT population consisting of all participants who received at least one dose of study drug was used for the safety analysis. AEs are presented according to the actual treatment administered (i.e., as treated). 2 participants that completed Part 2 MK-8723 10 mg/kg were re-enrolled in Part 2 MK-8723 100 mg/kg \& dosed per protocol procedure.	0.00% 0/6 • Up to 84 days The APaT population consisting of all participants who received at least one dose of study drug was used for the safety analysis. AEs are presented according to the actual treatment administered (i.e., as treated). 2 participants that completed Part 2 MK-8723 10 mg/kg were re-enrolled in Part 2 MK-8723 100 mg/kg \& dosed per protocol procedure.	0.00% 0/6 • Up to 84 days The APaT population consisting of all participants who received at least one dose of study drug was used for the safety analysis. AEs are presented according to the actual treatment administered (i.e., as treated). 2 participants that completed Part 2 MK-8723 10 mg/kg were re-enrolled in Part 2 MK-8723 100 mg/kg \& dosed per protocol procedure.	0.00% 0/10 • Up to 84 days The APaT population consisting of all participants who received at least one dose of study drug was used for the safety analysis. AEs are presented according to the actual treatment administered (i.e., as treated). 2 participants that completed Part 2 MK-8723 10 mg/kg were re-enrolled in Part 2 MK-8723 100 mg/kg \& dosed per protocol procedure.	0.00% 0/3 • Up to 84 days The APaT population consisting of all participants who received at least one dose of study drug was used for the safety analysis. AEs are presented according to the actual treatment administered (i.e., as treated). 2 participants that completed Part 2 MK-8723 10 mg/kg were re-enrolled in Part 2 MK-8723 100 mg/kg \& dosed per protocol procedure.	0.00% 0/2 • Up to 84 days The APaT population consisting of all participants who received at least one dose of study drug was used for the safety analysis. AEs are presented according to the actual treatment administered (i.e., as treated). 2 participants that completed Part 2 MK-8723 10 mg/kg were re-enrolled in Part 2 MK-8723 100 mg/kg \& dosed per protocol procedure.	66.7% 2/3 • Number of events 2 • Up to 84 days The APaT population consisting of all participants who received at least one dose of study drug was used for the safety analysis. AEs are presented according to the actual treatment administered (i.e., as treated). 2 participants that completed Part 2 MK-8723 10 mg/kg were re-enrolled in Part 2 MK-8723 100 mg/kg \& dosed per protocol procedure.	0.00% 0/4 • Up to 84 days The APaT population consisting of all participants who received at least one dose of study drug was used for the safety analysis. AEs are presented according to the actual treatment administered (i.e., as treated). 2 participants that completed Part 2 MK-8723 10 mg/kg were re-enrolled in Part 2 MK-8723 100 mg/kg \& dosed per protocol procedure.
Infections and infestations Infectious mononucleosis	0.00% 0/6 • Up to 84 days The APaT population consisting of all participants who received at least one dose of study drug was used for the safety analysis. AEs are presented according to the actual treatment administered (i.e., as treated). 2 participants that completed Part 2 MK-8723 10 mg/kg were re-enrolled in Part 2 MK-8723 100 mg/kg \& dosed per protocol procedure.	0.00% 0/6 • Up to 84 days The APaT population consisting of all participants who received at least one dose of study drug was used for the safety analysis. AEs are presented according to the actual treatment administered (i.e., as treated). 2 participants that completed Part 2 MK-8723 10 mg/kg were re-enrolled in Part 2 MK-8723 100 mg/kg \& dosed per protocol procedure.	0.00% 0/6 • Up to 84 days The APaT population consisting of all participants who received at least one dose of study drug was used for the safety analysis. AEs are presented according to the actual treatment administered (i.e., as treated). 2 participants that completed Part 2 MK-8723 10 mg/kg were re-enrolled in Part 2 MK-8723 100 mg/kg \& dosed per protocol procedure.	16.7% 1/6 • Number of events 1 • Up to 84 days The APaT population consisting of all participants who received at least one dose of study drug was used for the safety analysis. AEs are presented according to the actual treatment administered (i.e., as treated). 2 participants that completed Part 2 MK-8723 10 mg/kg were re-enrolled in Part 2 MK-8723 100 mg/kg \& dosed per protocol procedure.	0.00% 0/6 • Up to 84 days The APaT population consisting of all participants who received at least one dose of study drug was used for the safety analysis. AEs are presented according to the actual treatment administered (i.e., as treated). 2 participants that completed Part 2 MK-8723 10 mg/kg were re-enrolled in Part 2 MK-8723 100 mg/kg \& dosed per protocol procedure.	0.00% 0/10 • Up to 84 days The APaT population consisting of all participants who received at least one dose of study drug was used for the safety analysis. AEs are presented according to the actual treatment administered (i.e., as treated). 2 participants that completed Part 2 MK-8723 10 mg/kg were re-enrolled in Part 2 MK-8723 100 mg/kg \& dosed per protocol procedure.	0.00% 0/3 • Up to 84 days The APaT population consisting of all participants who received at least one dose of study drug was used for the safety analysis. AEs are presented according to the actual treatment administered (i.e., as treated). 2 participants that completed Part 2 MK-8723 10 mg/kg were re-enrolled in Part 2 MK-8723 100 mg/kg \& dosed per protocol procedure.	0.00% 0/2 • Up to 84 days The APaT population consisting of all participants who received at least one dose of study drug was used for the safety analysis. AEs are presented according to the actual treatment administered (i.e., as treated). 2 participants that completed Part 2 MK-8723 10 mg/kg were re-enrolled in Part 2 MK-8723 100 mg/kg \& dosed per protocol procedure.	0.00% 0/3 • Up to 84 days The APaT population consisting of all participants who received at least one dose of study drug was used for the safety analysis. AEs are presented according to the actual treatment administered (i.e., as treated). 2 participants that completed Part 2 MK-8723 10 mg/kg were re-enrolled in Part 2 MK-8723 100 mg/kg \& dosed per protocol procedure.	0.00% 0/4 • Up to 84 days The APaT population consisting of all participants who received at least one dose of study drug was used for the safety analysis. AEs are presented according to the actual treatment administered (i.e., as treated). 2 participants that completed Part 2 MK-8723 10 mg/kg were re-enrolled in Part 2 MK-8723 100 mg/kg \& dosed per protocol procedure.
Infections and infestations Upper respiratory tract infection	33.3% 2/6 • Number of events 2 • Up to 84 days The APaT population consisting of all participants who received at least one dose of study drug was used for the safety analysis. AEs are presented according to the actual treatment administered (i.e., as treated). 2 participants that completed Part 2 MK-8723 10 mg/kg were re-enrolled in Part 2 MK-8723 100 mg/kg \& dosed per protocol procedure.	0.00% 0/6 • Up to 84 days The APaT population consisting of all participants who received at least one dose of study drug was used for the safety analysis. AEs are presented according to the actual treatment administered (i.e., as treated). 2 participants that completed Part 2 MK-8723 10 mg/kg were re-enrolled in Part 2 MK-8723 100 mg/kg \& dosed per protocol procedure.	16.7% 1/6 • Number of events 1 • Up to 84 days The APaT population consisting of all participants who received at least one dose of study drug was used for the safety analysis. AEs are presented according to the actual treatment administered (i.e., as treated). 2 participants that completed Part 2 MK-8723 10 mg/kg were re-enrolled in Part 2 MK-8723 100 mg/kg \& dosed per protocol procedure.	16.7% 1/6 • Number of events 1 • Up to 84 days The APaT population consisting of all participants who received at least one dose of study drug was used for the safety analysis. AEs are presented according to the actual treatment administered (i.e., as treated). 2 participants that completed Part 2 MK-8723 10 mg/kg were re-enrolled in Part 2 MK-8723 100 mg/kg \& dosed per protocol procedure.	50.0% 3/6 • Number of events 3 • Up to 84 days The APaT population consisting of all participants who received at least one dose of study drug was used for the safety analysis. AEs are presented according to the actual treatment administered (i.e., as treated). 2 participants that completed Part 2 MK-8723 10 mg/kg were re-enrolled in Part 2 MK-8723 100 mg/kg \& dosed per protocol procedure.	50.0% 5/10 • Number of events 6 • Up to 84 days The APaT population consisting of all participants who received at least one dose of study drug was used for the safety analysis. AEs are presented according to the actual treatment administered (i.e., as treated). 2 participants that completed Part 2 MK-8723 10 mg/kg were re-enrolled in Part 2 MK-8723 100 mg/kg \& dosed per protocol procedure.	0.00% 0/3 • Up to 84 days The APaT population consisting of all participants who received at least one dose of study drug was used for the safety analysis. AEs are presented according to the actual treatment administered (i.e., as treated). 2 participants that completed Part 2 MK-8723 10 mg/kg were re-enrolled in Part 2 MK-8723 100 mg/kg \& dosed per protocol procedure.	50.0% 1/2 • Number of events 1 • Up to 84 days The APaT population consisting of all participants who received at least one dose of study drug was used for the safety analysis. AEs are presented according to the actual treatment administered (i.e., as treated). 2 participants that completed Part 2 MK-8723 10 mg/kg were re-enrolled in Part 2 MK-8723 100 mg/kg \& dosed per protocol procedure.	0.00% 0/3 • Up to 84 days The APaT population consisting of all participants who received at least one dose of study drug was used for the safety analysis. AEs are presented according to the actual treatment administered (i.e., as treated). 2 participants that completed Part 2 MK-8723 10 mg/kg were re-enrolled in Part 2 MK-8723 100 mg/kg \& dosed per protocol procedure.	50.0% 2/4 • Number of events 2 • Up to 84 days The APaT population consisting of all participants who received at least one dose of study drug was used for the safety analysis. AEs are presented according to the actual treatment administered (i.e., as treated). 2 participants that completed Part 2 MK-8723 10 mg/kg were re-enrolled in Part 2 MK-8723 100 mg/kg \& dosed per protocol procedure.
Injury, poisoning and procedural complications Wrist fracture	0.00% 0/6 • Up to 84 days The APaT population consisting of all participants who received at least one dose of study drug was used for the safety analysis. AEs are presented according to the actual treatment administered (i.e., as treated). 2 participants that completed Part 2 MK-8723 10 mg/kg were re-enrolled in Part 2 MK-8723 100 mg/kg \& dosed per protocol procedure.	0.00% 0/6 • Up to 84 days The APaT population consisting of all participants who received at least one dose of study drug was used for the safety analysis. AEs are presented according to the actual treatment administered (i.e., as treated). 2 participants that completed Part 2 MK-8723 10 mg/kg were re-enrolled in Part 2 MK-8723 100 mg/kg \& dosed per protocol procedure.	0.00% 0/6 • Up to 84 days The APaT population consisting of all participants who received at least one dose of study drug was used for the safety analysis. AEs are presented according to the actual treatment administered (i.e., as treated). 2 participants that completed Part 2 MK-8723 10 mg/kg were re-enrolled in Part 2 MK-8723 100 mg/kg \& dosed per protocol procedure.	0.00% 0/6 • Up to 84 days The APaT population consisting of all participants who received at least one dose of study drug was used for the safety analysis. AEs are presented according to the actual treatment administered (i.e., as treated). 2 participants that completed Part 2 MK-8723 10 mg/kg were re-enrolled in Part 2 MK-8723 100 mg/kg \& dosed per protocol procedure.	0.00% 0/6 • Up to 84 days The APaT population consisting of all participants who received at least one dose of study drug was used for the safety analysis. AEs are presented according to the actual treatment administered (i.e., as treated). 2 participants that completed Part 2 MK-8723 10 mg/kg were re-enrolled in Part 2 MK-8723 100 mg/kg \& dosed per protocol procedure.	10.0% 1/10 • Number of events 1 • Up to 84 days The APaT population consisting of all participants who received at least one dose of study drug was used for the safety analysis. AEs are presented according to the actual treatment administered (i.e., as treated). 2 participants that completed Part 2 MK-8723 10 mg/kg were re-enrolled in Part 2 MK-8723 100 mg/kg \& dosed per protocol procedure.	0.00% 0/3 • Up to 84 days The APaT population consisting of all participants who received at least one dose of study drug was used for the safety analysis. AEs are presented according to the actual treatment administered (i.e., as treated). 2 participants that completed Part 2 MK-8723 10 mg/kg were re-enrolled in Part 2 MK-8723 100 mg/kg \& dosed per protocol procedure.	0.00% 0/2 • Up to 84 days The APaT population consisting of all participants who received at least one dose of study drug was used for the safety analysis. AEs are presented according to the actual treatment administered (i.e., as treated). 2 participants that completed Part 2 MK-8723 10 mg/kg were re-enrolled in Part 2 MK-8723 100 mg/kg \& dosed per protocol procedure.	0.00% 0/3 • Up to 84 days The APaT population consisting of all participants who received at least one dose of study drug was used for the safety analysis. AEs are presented according to the actual treatment administered (i.e., as treated). 2 participants that completed Part 2 MK-8723 10 mg/kg were re-enrolled in Part 2 MK-8723 100 mg/kg \& dosed per protocol procedure.	0.00% 0/4 • Up to 84 days The APaT population consisting of all participants who received at least one dose of study drug was used for the safety analysis. AEs are presented according to the actual treatment administered (i.e., as treated). 2 participants that completed Part 2 MK-8723 10 mg/kg were re-enrolled in Part 2 MK-8723 100 mg/kg \& dosed per protocol procedure.
Investigations Alanine aminotransferase increased	0.00% 0/6 • Up to 84 days The APaT population consisting of all participants who received at least one dose of study drug was used for the safety analysis. AEs are presented according to the actual treatment administered (i.e., as treated). 2 participants that completed Part 2 MK-8723 10 mg/kg were re-enrolled in Part 2 MK-8723 100 mg/kg \& dosed per protocol procedure.	0.00% 0/6 • Up to 84 days The APaT population consisting of all participants who received at least one dose of study drug was used for the safety analysis. AEs are presented according to the actual treatment administered (i.e., as treated). 2 participants that completed Part 2 MK-8723 10 mg/kg were re-enrolled in Part 2 MK-8723 100 mg/kg \& dosed per protocol procedure.	0.00% 0/6 • Up to 84 days The APaT population consisting of all participants who received at least one dose of study drug was used for the safety analysis. AEs are presented according to the actual treatment administered (i.e., as treated). 2 participants that completed Part 2 MK-8723 10 mg/kg were re-enrolled in Part 2 MK-8723 100 mg/kg \& dosed per protocol procedure.	16.7% 1/6 • Number of events 1 • Up to 84 days The APaT population consisting of all participants who received at least one dose of study drug was used for the safety analysis. AEs are presented according to the actual treatment administered (i.e., as treated). 2 participants that completed Part 2 MK-8723 10 mg/kg were re-enrolled in Part 2 MK-8723 100 mg/kg \& dosed per protocol procedure.	0.00% 0/6 • Up to 84 days The APaT population consisting of all participants who received at least one dose of study drug was used for the safety analysis. AEs are presented according to the actual treatment administered (i.e., as treated). 2 participants that completed Part 2 MK-8723 10 mg/kg were re-enrolled in Part 2 MK-8723 100 mg/kg \& dosed per protocol procedure.	0.00% 0/10 • Up to 84 days The APaT population consisting of all participants who received at least one dose of study drug was used for the safety analysis. AEs are presented according to the actual treatment administered (i.e., as treated). 2 participants that completed Part 2 MK-8723 10 mg/kg were re-enrolled in Part 2 MK-8723 100 mg/kg \& dosed per protocol procedure.	0.00% 0/3 • Up to 84 days The APaT population consisting of all participants who received at least one dose of study drug was used for the safety analysis. AEs are presented according to the actual treatment administered (i.e., as treated). 2 participants that completed Part 2 MK-8723 10 mg/kg were re-enrolled in Part 2 MK-8723 100 mg/kg \& dosed per protocol procedure.	0.00% 0/2 • Up to 84 days The APaT population consisting of all participants who received at least one dose of study drug was used for the safety analysis. AEs are presented according to the actual treatment administered (i.e., as treated). 2 participants that completed Part 2 MK-8723 10 mg/kg were re-enrolled in Part 2 MK-8723 100 mg/kg \& dosed per protocol procedure.	0.00% 0/3 • Up to 84 days The APaT population consisting of all participants who received at least one dose of study drug was used for the safety analysis. AEs are presented according to the actual treatment administered (i.e., as treated). 2 participants that completed Part 2 MK-8723 10 mg/kg were re-enrolled in Part 2 MK-8723 100 mg/kg \& dosed per protocol procedure.	0.00% 0/4 • Up to 84 days The APaT population consisting of all participants who received at least one dose of study drug was used for the safety analysis. AEs are presented according to the actual treatment administered (i.e., as treated). 2 participants that completed Part 2 MK-8723 10 mg/kg were re-enrolled in Part 2 MK-8723 100 mg/kg \& dosed per protocol procedure.
Investigations Aspartate aminotransferase increased	0.00% 0/6 • Up to 84 days The APaT population consisting of all participants who received at least one dose of study drug was used for the safety analysis. AEs are presented according to the actual treatment administered (i.e., as treated). 2 participants that completed Part 2 MK-8723 10 mg/kg were re-enrolled in Part 2 MK-8723 100 mg/kg \& dosed per protocol procedure.	0.00% 0/6 • Up to 84 days The APaT population consisting of all participants who received at least one dose of study drug was used for the safety analysis. AEs are presented according to the actual treatment administered (i.e., as treated). 2 participants that completed Part 2 MK-8723 10 mg/kg were re-enrolled in Part 2 MK-8723 100 mg/kg \& dosed per protocol procedure.	0.00% 0/6 • Up to 84 days The APaT population consisting of all participants who received at least one dose of study drug was used for the safety analysis. AEs are presented according to the actual treatment administered (i.e., as treated). 2 participants that completed Part 2 MK-8723 10 mg/kg were re-enrolled in Part 2 MK-8723 100 mg/kg \& dosed per protocol procedure.	16.7% 1/6 • Number of events 1 • Up to 84 days The APaT population consisting of all participants who received at least one dose of study drug was used for the safety analysis. AEs are presented according to the actual treatment administered (i.e., as treated). 2 participants that completed Part 2 MK-8723 10 mg/kg were re-enrolled in Part 2 MK-8723 100 mg/kg \& dosed per protocol procedure.	0.00% 0/6 • Up to 84 days The APaT population consisting of all participants who received at least one dose of study drug was used for the safety analysis. AEs are presented according to the actual treatment administered (i.e., as treated). 2 participants that completed Part 2 MK-8723 10 mg/kg were re-enrolled in Part 2 MK-8723 100 mg/kg \& dosed per protocol procedure.	0.00% 0/10 • Up to 84 days The APaT population consisting of all participants who received at least one dose of study drug was used for the safety analysis. AEs are presented according to the actual treatment administered (i.e., as treated). 2 participants that completed Part 2 MK-8723 10 mg/kg were re-enrolled in Part 2 MK-8723 100 mg/kg \& dosed per protocol procedure.	0.00% 0/3 • Up to 84 days The APaT population consisting of all participants who received at least one dose of study drug was used for the safety analysis. AEs are presented according to the actual treatment administered (i.e., as treated). 2 participants that completed Part 2 MK-8723 10 mg/kg were re-enrolled in Part 2 MK-8723 100 mg/kg \& dosed per protocol procedure.	0.00% 0/2 • Up to 84 days The APaT population consisting of all participants who received at least one dose of study drug was used for the safety analysis. AEs are presented according to the actual treatment administered (i.e., as treated). 2 participants that completed Part 2 MK-8723 10 mg/kg were re-enrolled in Part 2 MK-8723 100 mg/kg \& dosed per protocol procedure.	0.00% 0/3 • Up to 84 days The APaT population consisting of all participants who received at least one dose of study drug was used for the safety analysis. AEs are presented according to the actual treatment administered (i.e., as treated). 2 participants that completed Part 2 MK-8723 10 mg/kg were re-enrolled in Part 2 MK-8723 100 mg/kg \& dosed per protocol procedure.	0.00% 0/4 • Up to 84 days The APaT population consisting of all participants who received at least one dose of study drug was used for the safety analysis. AEs are presented according to the actual treatment administered (i.e., as treated). 2 participants that completed Part 2 MK-8723 10 mg/kg were re-enrolled in Part 2 MK-8723 100 mg/kg \& dosed per protocol procedure.
Musculoskeletal and connective tissue disorders Back pain	0.00% 0/6 • Up to 84 days The APaT population consisting of all participants who received at least one dose of study drug was used for the safety analysis. AEs are presented according to the actual treatment administered (i.e., as treated). 2 participants that completed Part 2 MK-8723 10 mg/kg were re-enrolled in Part 2 MK-8723 100 mg/kg \& dosed per protocol procedure.	0.00% 0/6 • Up to 84 days The APaT population consisting of all participants who received at least one dose of study drug was used for the safety analysis. AEs are presented according to the actual treatment administered (i.e., as treated). 2 participants that completed Part 2 MK-8723 10 mg/kg were re-enrolled in Part 2 MK-8723 100 mg/kg \& dosed per protocol procedure.	0.00% 0/6 • Up to 84 days The APaT population consisting of all participants who received at least one dose of study drug was used for the safety analysis. AEs are presented according to the actual treatment administered (i.e., as treated). 2 participants that completed Part 2 MK-8723 10 mg/kg were re-enrolled in Part 2 MK-8723 100 mg/kg \& dosed per protocol procedure.	0.00% 0/6 • Up to 84 days The APaT population consisting of all participants who received at least one dose of study drug was used for the safety analysis. AEs are presented according to the actual treatment administered (i.e., as treated). 2 participants that completed Part 2 MK-8723 10 mg/kg were re-enrolled in Part 2 MK-8723 100 mg/kg \& dosed per protocol procedure.	0.00% 0/6 • Up to 84 days The APaT population consisting of all participants who received at least one dose of study drug was used for the safety analysis. AEs are presented according to the actual treatment administered (i.e., as treated). 2 participants that completed Part 2 MK-8723 10 mg/kg were re-enrolled in Part 2 MK-8723 100 mg/kg \& dosed per protocol procedure.	0.00% 0/10 • Up to 84 days The APaT population consisting of all participants who received at least one dose of study drug was used for the safety analysis. AEs are presented according to the actual treatment administered (i.e., as treated). 2 participants that completed Part 2 MK-8723 10 mg/kg were re-enrolled in Part 2 MK-8723 100 mg/kg \& dosed per protocol procedure.	0.00% 0/3 • Up to 84 days The APaT population consisting of all participants who received at least one dose of study drug was used for the safety analysis. AEs are presented according to the actual treatment administered (i.e., as treated). 2 participants that completed Part 2 MK-8723 10 mg/kg were re-enrolled in Part 2 MK-8723 100 mg/kg \& dosed per protocol procedure.	0.00% 0/2 • Up to 84 days The APaT population consisting of all participants who received at least one dose of study drug was used for the safety analysis. AEs are presented according to the actual treatment administered (i.e., as treated). 2 participants that completed Part 2 MK-8723 10 mg/kg were re-enrolled in Part 2 MK-8723 100 mg/kg \& dosed per protocol procedure.	0.00% 0/3 • Up to 84 days The APaT population consisting of all participants who received at least one dose of study drug was used for the safety analysis. AEs are presented according to the actual treatment administered (i.e., as treated). 2 participants that completed Part 2 MK-8723 10 mg/kg were re-enrolled in Part 2 MK-8723 100 mg/kg \& dosed per protocol procedure.	25.0% 1/4 • Number of events 1 • Up to 84 days The APaT population consisting of all participants who received at least one dose of study drug was used for the safety analysis. AEs are presented according to the actual treatment administered (i.e., as treated). 2 participants that completed Part 2 MK-8723 10 mg/kg were re-enrolled in Part 2 MK-8723 100 mg/kg \& dosed per protocol procedure.
Musculoskeletal and connective tissue disorders Myalgia	0.00% 0/6 • Up to 84 days The APaT population consisting of all participants who received at least one dose of study drug was used for the safety analysis. AEs are presented according to the actual treatment administered (i.e., as treated). 2 participants that completed Part 2 MK-8723 10 mg/kg were re-enrolled in Part 2 MK-8723 100 mg/kg \& dosed per protocol procedure.	0.00% 0/6 • Up to 84 days The APaT population consisting of all participants who received at least one dose of study drug was used for the safety analysis. AEs are presented according to the actual treatment administered (i.e., as treated). 2 participants that completed Part 2 MK-8723 10 mg/kg were re-enrolled in Part 2 MK-8723 100 mg/kg \& dosed per protocol procedure.	16.7% 1/6 • Number of events 1 • Up to 84 days The APaT population consisting of all participants who received at least one dose of study drug was used for the safety analysis. AEs are presented according to the actual treatment administered (i.e., as treated). 2 participants that completed Part 2 MK-8723 10 mg/kg were re-enrolled in Part 2 MK-8723 100 mg/kg \& dosed per protocol procedure.	0.00% 0/6 • Up to 84 days The APaT population consisting of all participants who received at least one dose of study drug was used for the safety analysis. AEs are presented according to the actual treatment administered (i.e., as treated). 2 participants that completed Part 2 MK-8723 10 mg/kg were re-enrolled in Part 2 MK-8723 100 mg/kg \& dosed per protocol procedure.	0.00% 0/6 • Up to 84 days The APaT population consisting of all participants who received at least one dose of study drug was used for the safety analysis. AEs are presented according to the actual treatment administered (i.e., as treated). 2 participants that completed Part 2 MK-8723 10 mg/kg were re-enrolled in Part 2 MK-8723 100 mg/kg \& dosed per protocol procedure.	0.00% 0/10 • Up to 84 days The APaT population consisting of all participants who received at least one dose of study drug was used for the safety analysis. AEs are presented according to the actual treatment administered (i.e., as treated). 2 participants that completed Part 2 MK-8723 10 mg/kg were re-enrolled in Part 2 MK-8723 100 mg/kg \& dosed per protocol procedure.	0.00% 0/3 • Up to 84 days The APaT population consisting of all participants who received at least one dose of study drug was used for the safety analysis. AEs are presented according to the actual treatment administered (i.e., as treated). 2 participants that completed Part 2 MK-8723 10 mg/kg were re-enrolled in Part 2 MK-8723 100 mg/kg \& dosed per protocol procedure.	0.00% 0/2 • Up to 84 days The APaT population consisting of all participants who received at least one dose of study drug was used for the safety analysis. AEs are presented according to the actual treatment administered (i.e., as treated). 2 participants that completed Part 2 MK-8723 10 mg/kg were re-enrolled in Part 2 MK-8723 100 mg/kg \& dosed per protocol procedure.	0.00% 0/3 • Up to 84 days The APaT population consisting of all participants who received at least one dose of study drug was used for the safety analysis. AEs are presented according to the actual treatment administered (i.e., as treated). 2 participants that completed Part 2 MK-8723 10 mg/kg were re-enrolled in Part 2 MK-8723 100 mg/kg \& dosed per protocol procedure.	0.00% 0/4 • Up to 84 days The APaT population consisting of all participants who received at least one dose of study drug was used for the safety analysis. AEs are presented according to the actual treatment administered (i.e., as treated). 2 participants that completed Part 2 MK-8723 10 mg/kg were re-enrolled in Part 2 MK-8723 100 mg/kg \& dosed per protocol procedure.
Musculoskeletal and connective tissue disorders Myalgia intercostal	0.00% 0/6 • Up to 84 days The APaT population consisting of all participants who received at least one dose of study drug was used for the safety analysis. AEs are presented according to the actual treatment administered (i.e., as treated). 2 participants that completed Part 2 MK-8723 10 mg/kg were re-enrolled in Part 2 MK-8723 100 mg/kg \& dosed per protocol procedure.	0.00% 0/6 • Up to 84 days The APaT population consisting of all participants who received at least one dose of study drug was used for the safety analysis. AEs are presented according to the actual treatment administered (i.e., as treated). 2 participants that completed Part 2 MK-8723 10 mg/kg were re-enrolled in Part 2 MK-8723 100 mg/kg \& dosed per protocol procedure.	0.00% 0/6 • Up to 84 days The APaT population consisting of all participants who received at least one dose of study drug was used for the safety analysis. AEs are presented according to the actual treatment administered (i.e., as treated). 2 participants that completed Part 2 MK-8723 10 mg/kg were re-enrolled in Part 2 MK-8723 100 mg/kg \& dosed per protocol procedure.	0.00% 0/6 • Up to 84 days The APaT population consisting of all participants who received at least one dose of study drug was used for the safety analysis. AEs are presented according to the actual treatment administered (i.e., as treated). 2 participants that completed Part 2 MK-8723 10 mg/kg were re-enrolled in Part 2 MK-8723 100 mg/kg \& dosed per protocol procedure.	16.7% 1/6 • Number of events 1 • Up to 84 days The APaT population consisting of all participants who received at least one dose of study drug was used for the safety analysis. AEs are presented according to the actual treatment administered (i.e., as treated). 2 participants that completed Part 2 MK-8723 10 mg/kg were re-enrolled in Part 2 MK-8723 100 mg/kg \& dosed per protocol procedure.	0.00% 0/10 • Up to 84 days The APaT population consisting of all participants who received at least one dose of study drug was used for the safety analysis. AEs are presented according to the actual treatment administered (i.e., as treated). 2 participants that completed Part 2 MK-8723 10 mg/kg were re-enrolled in Part 2 MK-8723 100 mg/kg \& dosed per protocol procedure.	0.00% 0/3 • Up to 84 days The APaT population consisting of all participants who received at least one dose of study drug was used for the safety analysis. AEs are presented according to the actual treatment administered (i.e., as treated). 2 participants that completed Part 2 MK-8723 10 mg/kg were re-enrolled in Part 2 MK-8723 100 mg/kg \& dosed per protocol procedure.	0.00% 0/2 • Up to 84 days The APaT population consisting of all participants who received at least one dose of study drug was used for the safety analysis. AEs are presented according to the actual treatment administered (i.e., as treated). 2 participants that completed Part 2 MK-8723 10 mg/kg were re-enrolled in Part 2 MK-8723 100 mg/kg \& dosed per protocol procedure.	0.00% 0/3 • Up to 84 days The APaT population consisting of all participants who received at least one dose of study drug was used for the safety analysis. AEs are presented according to the actual treatment administered (i.e., as treated). 2 participants that completed Part 2 MK-8723 10 mg/kg were re-enrolled in Part 2 MK-8723 100 mg/kg \& dosed per protocol procedure.	0.00% 0/4 • Up to 84 days The APaT population consisting of all participants who received at least one dose of study drug was used for the safety analysis. AEs are presented according to the actual treatment administered (i.e., as treated). 2 participants that completed Part 2 MK-8723 10 mg/kg were re-enrolled in Part 2 MK-8723 100 mg/kg \& dosed per protocol procedure.
Nervous system disorders Dizziness	0.00% 0/6 • Up to 84 days The APaT population consisting of all participants who received at least one dose of study drug was used for the safety analysis. AEs are presented according to the actual treatment administered (i.e., as treated). 2 participants that completed Part 2 MK-8723 10 mg/kg were re-enrolled in Part 2 MK-8723 100 mg/kg \& dosed per protocol procedure.	0.00% 0/6 • Up to 84 days The APaT population consisting of all participants who received at least one dose of study drug was used for the safety analysis. AEs are presented according to the actual treatment administered (i.e., as treated). 2 participants that completed Part 2 MK-8723 10 mg/kg were re-enrolled in Part 2 MK-8723 100 mg/kg \& dosed per protocol procedure.	0.00% 0/6 • Up to 84 days The APaT population consisting of all participants who received at least one dose of study drug was used for the safety analysis. AEs are presented according to the actual treatment administered (i.e., as treated). 2 participants that completed Part 2 MK-8723 10 mg/kg were re-enrolled in Part 2 MK-8723 100 mg/kg \& dosed per protocol procedure.	0.00% 0/6 • Up to 84 days The APaT population consisting of all participants who received at least one dose of study drug was used for the safety analysis. AEs are presented according to the actual treatment administered (i.e., as treated). 2 participants that completed Part 2 MK-8723 10 mg/kg were re-enrolled in Part 2 MK-8723 100 mg/kg \& dosed per protocol procedure.	0.00% 0/6 • Up to 84 days The APaT population consisting of all participants who received at least one dose of study drug was used for the safety analysis. AEs are presented according to the actual treatment administered (i.e., as treated). 2 participants that completed Part 2 MK-8723 10 mg/kg were re-enrolled in Part 2 MK-8723 100 mg/kg \& dosed per protocol procedure.	10.0% 1/10 • Number of events 1 • Up to 84 days The APaT population consisting of all participants who received at least one dose of study drug was used for the safety analysis. AEs are presented according to the actual treatment administered (i.e., as treated). 2 participants that completed Part 2 MK-8723 10 mg/kg were re-enrolled in Part 2 MK-8723 100 mg/kg \& dosed per protocol procedure.	0.00% 0/3 • Up to 84 days The APaT population consisting of all participants who received at least one dose of study drug was used for the safety analysis. AEs are presented according to the actual treatment administered (i.e., as treated). 2 participants that completed Part 2 MK-8723 10 mg/kg were re-enrolled in Part 2 MK-8723 100 mg/kg \& dosed per protocol procedure.	0.00% 0/2 • Up to 84 days The APaT population consisting of all participants who received at least one dose of study drug was used for the safety analysis. AEs are presented according to the actual treatment administered (i.e., as treated). 2 participants that completed Part 2 MK-8723 10 mg/kg were re-enrolled in Part 2 MK-8723 100 mg/kg \& dosed per protocol procedure.	0.00% 0/3 • Up to 84 days The APaT population consisting of all participants who received at least one dose of study drug was used for the safety analysis. AEs are presented according to the actual treatment administered (i.e., as treated). 2 participants that completed Part 2 MK-8723 10 mg/kg were re-enrolled in Part 2 MK-8723 100 mg/kg \& dosed per protocol procedure.	0.00% 0/4 • Up to 84 days The APaT population consisting of all participants who received at least one dose of study drug was used for the safety analysis. AEs are presented according to the actual treatment administered (i.e., as treated). 2 participants that completed Part 2 MK-8723 10 mg/kg were re-enrolled in Part 2 MK-8723 100 mg/kg \& dosed per protocol procedure.
Nervous system disorders Headache	16.7% 1/6 • Number of events 1 • Up to 84 days The APaT population consisting of all participants who received at least one dose of study drug was used for the safety analysis. AEs are presented according to the actual treatment administered (i.e., as treated). 2 participants that completed Part 2 MK-8723 10 mg/kg were re-enrolled in Part 2 MK-8723 100 mg/kg \& dosed per protocol procedure.	16.7% 1/6 • Number of events 1 • Up to 84 days The APaT population consisting of all participants who received at least one dose of study drug was used for the safety analysis. AEs are presented according to the actual treatment administered (i.e., as treated). 2 participants that completed Part 2 MK-8723 10 mg/kg were re-enrolled in Part 2 MK-8723 100 mg/kg \& dosed per protocol procedure.	33.3% 2/6 • Number of events 2 • Up to 84 days The APaT population consisting of all participants who received at least one dose of study drug was used for the safety analysis. AEs are presented according to the actual treatment administered (i.e., as treated). 2 participants that completed Part 2 MK-8723 10 mg/kg were re-enrolled in Part 2 MK-8723 100 mg/kg \& dosed per protocol procedure.	0.00% 0/6 • Up to 84 days The APaT population consisting of all participants who received at least one dose of study drug was used for the safety analysis. AEs are presented according to the actual treatment administered (i.e., as treated). 2 participants that completed Part 2 MK-8723 10 mg/kg were re-enrolled in Part 2 MK-8723 100 mg/kg \& dosed per protocol procedure.	0.00% 0/6 • Up to 84 days The APaT population consisting of all participants who received at least one dose of study drug was used for the safety analysis. AEs are presented according to the actual treatment administered (i.e., as treated). 2 participants that completed Part 2 MK-8723 10 mg/kg were re-enrolled in Part 2 MK-8723 100 mg/kg \& dosed per protocol procedure.	0.00% 0/10 • Up to 84 days The APaT population consisting of all participants who received at least one dose of study drug was used for the safety analysis. AEs are presented according to the actual treatment administered (i.e., as treated). 2 participants that completed Part 2 MK-8723 10 mg/kg were re-enrolled in Part 2 MK-8723 100 mg/kg \& dosed per protocol procedure.	33.3% 1/3 • Number of events 1 • Up to 84 days The APaT population consisting of all participants who received at least one dose of study drug was used for the safety analysis. AEs are presented according to the actual treatment administered (i.e., as treated). 2 participants that completed Part 2 MK-8723 10 mg/kg were re-enrolled in Part 2 MK-8723 100 mg/kg \& dosed per protocol procedure.	0.00% 0/2 • Up to 84 days The APaT population consisting of all participants who received at least one dose of study drug was used for the safety analysis. AEs are presented according to the actual treatment administered (i.e., as treated). 2 participants that completed Part 2 MK-8723 10 mg/kg were re-enrolled in Part 2 MK-8723 100 mg/kg \& dosed per protocol procedure.	0.00% 0/3 • Up to 84 days The APaT population consisting of all participants who received at least one dose of study drug was used for the safety analysis. AEs are presented according to the actual treatment administered (i.e., as treated). 2 participants that completed Part 2 MK-8723 10 mg/kg were re-enrolled in Part 2 MK-8723 100 mg/kg \& dosed per protocol procedure.	25.0% 1/4 • Number of events 1 • Up to 84 days The APaT population consisting of all participants who received at least one dose of study drug was used for the safety analysis. AEs are presented according to the actual treatment administered (i.e., as treated). 2 participants that completed Part 2 MK-8723 10 mg/kg were re-enrolled in Part 2 MK-8723 100 mg/kg \& dosed per protocol procedure.
Nervous system disorders Lethargy	0.00% 0/6 • Up to 84 days The APaT population consisting of all participants who received at least one dose of study drug was used for the safety analysis. AEs are presented according to the actual treatment administered (i.e., as treated). 2 participants that completed Part 2 MK-8723 10 mg/kg were re-enrolled in Part 2 MK-8723 100 mg/kg \& dosed per protocol procedure.	0.00% 0/6 • Up to 84 days The APaT population consisting of all participants who received at least one dose of study drug was used for the safety analysis. AEs are presented according to the actual treatment administered (i.e., as treated). 2 participants that completed Part 2 MK-8723 10 mg/kg were re-enrolled in Part 2 MK-8723 100 mg/kg \& dosed per protocol procedure.	16.7% 1/6 • Number of events 1 • Up to 84 days The APaT population consisting of all participants who received at least one dose of study drug was used for the safety analysis. AEs are presented according to the actual treatment administered (i.e., as treated). 2 participants that completed Part 2 MK-8723 10 mg/kg were re-enrolled in Part 2 MK-8723 100 mg/kg \& dosed per protocol procedure.	0.00% 0/6 • Up to 84 days The APaT population consisting of all participants who received at least one dose of study drug was used for the safety analysis. AEs are presented according to the actual treatment administered (i.e., as treated). 2 participants that completed Part 2 MK-8723 10 mg/kg were re-enrolled in Part 2 MK-8723 100 mg/kg \& dosed per protocol procedure.	0.00% 0/6 • Up to 84 days The APaT population consisting of all participants who received at least one dose of study drug was used for the safety analysis. AEs are presented according to the actual treatment administered (i.e., as treated). 2 participants that completed Part 2 MK-8723 10 mg/kg were re-enrolled in Part 2 MK-8723 100 mg/kg \& dosed per protocol procedure.	0.00% 0/10 • Up to 84 days The APaT population consisting of all participants who received at least one dose of study drug was used for the safety analysis. AEs are presented according to the actual treatment administered (i.e., as treated). 2 participants that completed Part 2 MK-8723 10 mg/kg were re-enrolled in Part 2 MK-8723 100 mg/kg \& dosed per protocol procedure.	0.00% 0/3 • Up to 84 days The APaT population consisting of all participants who received at least one dose of study drug was used for the safety analysis. AEs are presented according to the actual treatment administered (i.e., as treated). 2 participants that completed Part 2 MK-8723 10 mg/kg were re-enrolled in Part 2 MK-8723 100 mg/kg \& dosed per protocol procedure.	0.00% 0/2 • Up to 84 days The APaT population consisting of all participants who received at least one dose of study drug was used for the safety analysis. AEs are presented according to the actual treatment administered (i.e., as treated). 2 participants that completed Part 2 MK-8723 10 mg/kg were re-enrolled in Part 2 MK-8723 100 mg/kg \& dosed per protocol procedure.	0.00% 0/3 • Up to 84 days The APaT population consisting of all participants who received at least one dose of study drug was used for the safety analysis. AEs are presented according to the actual treatment administered (i.e., as treated). 2 participants that completed Part 2 MK-8723 10 mg/kg were re-enrolled in Part 2 MK-8723 100 mg/kg \& dosed per protocol procedure.	0.00% 0/4 • Up to 84 days The APaT population consisting of all participants who received at least one dose of study drug was used for the safety analysis. AEs are presented according to the actual treatment administered (i.e., as treated). 2 participants that completed Part 2 MK-8723 10 mg/kg were re-enrolled in Part 2 MK-8723 100 mg/kg \& dosed per protocol procedure.
Nervous system disorders Presyncope	0.00% 0/6 • Up to 84 days The APaT population consisting of all participants who received at least one dose of study drug was used for the safety analysis. AEs are presented according to the actual treatment administered (i.e., as treated). 2 participants that completed Part 2 MK-8723 10 mg/kg were re-enrolled in Part 2 MK-8723 100 mg/kg \& dosed per protocol procedure.	0.00% 0/6 • Up to 84 days The APaT population consisting of all participants who received at least one dose of study drug was used for the safety analysis. AEs are presented according to the actual treatment administered (i.e., as treated). 2 participants that completed Part 2 MK-8723 10 mg/kg were re-enrolled in Part 2 MK-8723 100 mg/kg \& dosed per protocol procedure.	0.00% 0/6 • Up to 84 days The APaT population consisting of all participants who received at least one dose of study drug was used for the safety analysis. AEs are presented according to the actual treatment administered (i.e., as treated). 2 participants that completed Part 2 MK-8723 10 mg/kg were re-enrolled in Part 2 MK-8723 100 mg/kg \& dosed per protocol procedure.	0.00% 0/6 • Up to 84 days The APaT population consisting of all participants who received at least one dose of study drug was used for the safety analysis. AEs are presented according to the actual treatment administered (i.e., as treated). 2 participants that completed Part 2 MK-8723 10 mg/kg were re-enrolled in Part 2 MK-8723 100 mg/kg \& dosed per protocol procedure.	16.7% 1/6 • Number of events 1 • Up to 84 days The APaT population consisting of all participants who received at least one dose of study drug was used for the safety analysis. AEs are presented according to the actual treatment administered (i.e., as treated). 2 participants that completed Part 2 MK-8723 10 mg/kg were re-enrolled in Part 2 MK-8723 100 mg/kg \& dosed per protocol procedure.	0.00% 0/10 • Up to 84 days The APaT population consisting of all participants who received at least one dose of study drug was used for the safety analysis. AEs are presented according to the actual treatment administered (i.e., as treated). 2 participants that completed Part 2 MK-8723 10 mg/kg were re-enrolled in Part 2 MK-8723 100 mg/kg \& dosed per protocol procedure.	0.00% 0/3 • Up to 84 days The APaT population consisting of all participants who received at least one dose of study drug was used for the safety analysis. AEs are presented according to the actual treatment administered (i.e., as treated). 2 participants that completed Part 2 MK-8723 10 mg/kg were re-enrolled in Part 2 MK-8723 100 mg/kg \& dosed per protocol procedure.	0.00% 0/2 • Up to 84 days The APaT population consisting of all participants who received at least one dose of study drug was used for the safety analysis. AEs are presented according to the actual treatment administered (i.e., as treated). 2 participants that completed Part 2 MK-8723 10 mg/kg were re-enrolled in Part 2 MK-8723 100 mg/kg \& dosed per protocol procedure.	0.00% 0/3 • Up to 84 days The APaT population consisting of all participants who received at least one dose of study drug was used for the safety analysis. AEs are presented according to the actual treatment administered (i.e., as treated). 2 participants that completed Part 2 MK-8723 10 mg/kg were re-enrolled in Part 2 MK-8723 100 mg/kg \& dosed per protocol procedure.	0.00% 0/4 • Up to 84 days The APaT population consisting of all participants who received at least one dose of study drug was used for the safety analysis. AEs are presented according to the actual treatment administered (i.e., as treated). 2 participants that completed Part 2 MK-8723 10 mg/kg were re-enrolled in Part 2 MK-8723 100 mg/kg \& dosed per protocol procedure.
Psychiatric disorders Anxiety	0.00% 0/6 • Up to 84 days The APaT population consisting of all participants who received at least one dose of study drug was used for the safety analysis. AEs are presented according to the actual treatment administered (i.e., as treated). 2 participants that completed Part 2 MK-8723 10 mg/kg were re-enrolled in Part 2 MK-8723 100 mg/kg \& dosed per protocol procedure.	0.00% 0/6 • Up to 84 days The APaT population consisting of all participants who received at least one dose of study drug was used for the safety analysis. AEs are presented according to the actual treatment administered (i.e., as treated). 2 participants that completed Part 2 MK-8723 10 mg/kg were re-enrolled in Part 2 MK-8723 100 mg/kg \& dosed per protocol procedure.	0.00% 0/6 • Up to 84 days The APaT population consisting of all participants who received at least one dose of study drug was used for the safety analysis. AEs are presented according to the actual treatment administered (i.e., as treated). 2 participants that completed Part 2 MK-8723 10 mg/kg were re-enrolled in Part 2 MK-8723 100 mg/kg \& dosed per protocol procedure.	0.00% 0/6 • Up to 84 days The APaT population consisting of all participants who received at least one dose of study drug was used for the safety analysis. AEs are presented according to the actual treatment administered (i.e., as treated). 2 participants that completed Part 2 MK-8723 10 mg/kg were re-enrolled in Part 2 MK-8723 100 mg/kg \& dosed per protocol procedure.	0.00% 0/6 • Up to 84 days The APaT population consisting of all participants who received at least one dose of study drug was used for the safety analysis. AEs are presented according to the actual treatment administered (i.e., as treated). 2 participants that completed Part 2 MK-8723 10 mg/kg were re-enrolled in Part 2 MK-8723 100 mg/kg \& dosed per protocol procedure.	10.0% 1/10 • Number of events 1 • Up to 84 days The APaT population consisting of all participants who received at least one dose of study drug was used for the safety analysis. AEs are presented according to the actual treatment administered (i.e., as treated). 2 participants that completed Part 2 MK-8723 10 mg/kg were re-enrolled in Part 2 MK-8723 100 mg/kg \& dosed per protocol procedure.	0.00% 0/3 • Up to 84 days The APaT population consisting of all participants who received at least one dose of study drug was used for the safety analysis. AEs are presented according to the actual treatment administered (i.e., as treated). 2 participants that completed Part 2 MK-8723 10 mg/kg were re-enrolled in Part 2 MK-8723 100 mg/kg \& dosed per protocol procedure.	0.00% 0/2 • Up to 84 days The APaT population consisting of all participants who received at least one dose of study drug was used for the safety analysis. AEs are presented according to the actual treatment administered (i.e., as treated). 2 participants that completed Part 2 MK-8723 10 mg/kg were re-enrolled in Part 2 MK-8723 100 mg/kg \& dosed per protocol procedure.	0.00% 0/3 • Up to 84 days The APaT population consisting of all participants who received at least one dose of study drug was used for the safety analysis. AEs are presented according to the actual treatment administered (i.e., as treated). 2 participants that completed Part 2 MK-8723 10 mg/kg were re-enrolled in Part 2 MK-8723 100 mg/kg \& dosed per protocol procedure.	0.00% 0/4 • Up to 84 days The APaT population consisting of all participants who received at least one dose of study drug was used for the safety analysis. AEs are presented according to the actual treatment administered (i.e., as treated). 2 participants that completed Part 2 MK-8723 10 mg/kg were re-enrolled in Part 2 MK-8723 100 mg/kg \& dosed per protocol procedure.
Psychiatric disorders Insomnia	0.00% 0/6 • Up to 84 days The APaT population consisting of all participants who received at least one dose of study drug was used for the safety analysis. AEs are presented according to the actual treatment administered (i.e., as treated). 2 participants that completed Part 2 MK-8723 10 mg/kg were re-enrolled in Part 2 MK-8723 100 mg/kg \& dosed per protocol procedure.	0.00% 0/6 • Up to 84 days The APaT population consisting of all participants who received at least one dose of study drug was used for the safety analysis. AEs are presented according to the actual treatment administered (i.e., as treated). 2 participants that completed Part 2 MK-8723 10 mg/kg were re-enrolled in Part 2 MK-8723 100 mg/kg \& dosed per protocol procedure.	0.00% 0/6 • Up to 84 days The APaT population consisting of all participants who received at least one dose of study drug was used for the safety analysis. AEs are presented according to the actual treatment administered (i.e., as treated). 2 participants that completed Part 2 MK-8723 10 mg/kg were re-enrolled in Part 2 MK-8723 100 mg/kg \& dosed per protocol procedure.	0.00% 0/6 • Up to 84 days The APaT population consisting of all participants who received at least one dose of study drug was used for the safety analysis. AEs are presented according to the actual treatment administered (i.e., as treated). 2 participants that completed Part 2 MK-8723 10 mg/kg were re-enrolled in Part 2 MK-8723 100 mg/kg \& dosed per protocol procedure.	0.00% 0/6 • Up to 84 days The APaT population consisting of all participants who received at least one dose of study drug was used for the safety analysis. AEs are presented according to the actual treatment administered (i.e., as treated). 2 participants that completed Part 2 MK-8723 10 mg/kg were re-enrolled in Part 2 MK-8723 100 mg/kg \& dosed per protocol procedure.	10.0% 1/10 • Number of events 1 • Up to 84 days The APaT population consisting of all participants who received at least one dose of study drug was used for the safety analysis. AEs are presented according to the actual treatment administered (i.e., as treated). 2 participants that completed Part 2 MK-8723 10 mg/kg were re-enrolled in Part 2 MK-8723 100 mg/kg \& dosed per protocol procedure.	0.00% 0/3 • Up to 84 days The APaT population consisting of all participants who received at least one dose of study drug was used for the safety analysis. AEs are presented according to the actual treatment administered (i.e., as treated). 2 participants that completed Part 2 MK-8723 10 mg/kg were re-enrolled in Part 2 MK-8723 100 mg/kg \& dosed per protocol procedure.	0.00% 0/2 • Up to 84 days The APaT population consisting of all participants who received at least one dose of study drug was used for the safety analysis. AEs are presented according to the actual treatment administered (i.e., as treated). 2 participants that completed Part 2 MK-8723 10 mg/kg were re-enrolled in Part 2 MK-8723 100 mg/kg \& dosed per protocol procedure.	0.00% 0/3 • Up to 84 days The APaT population consisting of all participants who received at least one dose of study drug was used for the safety analysis. AEs are presented according to the actual treatment administered (i.e., as treated). 2 participants that completed Part 2 MK-8723 10 mg/kg were re-enrolled in Part 2 MK-8723 100 mg/kg \& dosed per protocol procedure.	0.00% 0/4 • Up to 84 days The APaT population consisting of all participants who received at least one dose of study drug was used for the safety analysis. AEs are presented according to the actual treatment administered (i.e., as treated). 2 participants that completed Part 2 MK-8723 10 mg/kg were re-enrolled in Part 2 MK-8723 100 mg/kg \& dosed per protocol procedure.
Respiratory, thoracic and mediastinal disorders Asthma	0.00% 0/6 • Up to 84 days The APaT population consisting of all participants who received at least one dose of study drug was used for the safety analysis. AEs are presented according to the actual treatment administered (i.e., as treated). 2 participants that completed Part 2 MK-8723 10 mg/kg were re-enrolled in Part 2 MK-8723 100 mg/kg \& dosed per protocol procedure.	0.00% 0/6 • Up to 84 days The APaT population consisting of all participants who received at least one dose of study drug was used for the safety analysis. AEs are presented according to the actual treatment administered (i.e., as treated). 2 participants that completed Part 2 MK-8723 10 mg/kg were re-enrolled in Part 2 MK-8723 100 mg/kg \& dosed per protocol procedure.	0.00% 0/6 • Up to 84 days The APaT population consisting of all participants who received at least one dose of study drug was used for the safety analysis. AEs are presented according to the actual treatment administered (i.e., as treated). 2 participants that completed Part 2 MK-8723 10 mg/kg were re-enrolled in Part 2 MK-8723 100 mg/kg \& dosed per protocol procedure.	0.00% 0/6 • Up to 84 days The APaT population consisting of all participants who received at least one dose of study drug was used for the safety analysis. AEs are presented according to the actual treatment administered (i.e., as treated). 2 participants that completed Part 2 MK-8723 10 mg/kg were re-enrolled in Part 2 MK-8723 100 mg/kg \& dosed per protocol procedure.	0.00% 0/6 • Up to 84 days The APaT population consisting of all participants who received at least one dose of study drug was used for the safety analysis. AEs are presented according to the actual treatment administered (i.e., as treated). 2 participants that completed Part 2 MK-8723 10 mg/kg were re-enrolled in Part 2 MK-8723 100 mg/kg \& dosed per protocol procedure.	10.0% 1/10 • Number of events 1 • Up to 84 days The APaT population consisting of all participants who received at least one dose of study drug was used for the safety analysis. AEs are presented according to the actual treatment administered (i.e., as treated). 2 participants that completed Part 2 MK-8723 10 mg/kg were re-enrolled in Part 2 MK-8723 100 mg/kg \& dosed per protocol procedure.	0.00% 0/3 • Up to 84 days The APaT population consisting of all participants who received at least one dose of study drug was used for the safety analysis. AEs are presented according to the actual treatment administered (i.e., as treated). 2 participants that completed Part 2 MK-8723 10 mg/kg were re-enrolled in Part 2 MK-8723 100 mg/kg \& dosed per protocol procedure.	0.00% 0/2 • Up to 84 days The APaT population consisting of all participants who received at least one dose of study drug was used for the safety analysis. AEs are presented according to the actual treatment administered (i.e., as treated). 2 participants that completed Part 2 MK-8723 10 mg/kg were re-enrolled in Part 2 MK-8723 100 mg/kg \& dosed per protocol procedure.	0.00% 0/3 • Up to 84 days The APaT population consisting of all participants who received at least one dose of study drug was used for the safety analysis. AEs are presented according to the actual treatment administered (i.e., as treated). 2 participants that completed Part 2 MK-8723 10 mg/kg were re-enrolled in Part 2 MK-8723 100 mg/kg \& dosed per protocol procedure.	0.00% 0/4 • Up to 84 days The APaT population consisting of all participants who received at least one dose of study drug was used for the safety analysis. AEs are presented according to the actual treatment administered (i.e., as treated). 2 participants that completed Part 2 MK-8723 10 mg/kg were re-enrolled in Part 2 MK-8723 100 mg/kg \& dosed per protocol procedure.
Skin and subcutaneous tissue disorders Blood blister	0.00% 0/6 • Up to 84 days The APaT population consisting of all participants who received at least one dose of study drug was used for the safety analysis. AEs are presented according to the actual treatment administered (i.e., as treated). 2 participants that completed Part 2 MK-8723 10 mg/kg were re-enrolled in Part 2 MK-8723 100 mg/kg \& dosed per protocol procedure.	0.00% 0/6 • Up to 84 days The APaT population consisting of all participants who received at least one dose of study drug was used for the safety analysis. AEs are presented according to the actual treatment administered (i.e., as treated). 2 participants that completed Part 2 MK-8723 10 mg/kg were re-enrolled in Part 2 MK-8723 100 mg/kg \& dosed per protocol procedure.	0.00% 0/6 • Up to 84 days The APaT population consisting of all participants who received at least one dose of study drug was used for the safety analysis. AEs are presented according to the actual treatment administered (i.e., as treated). 2 participants that completed Part 2 MK-8723 10 mg/kg were re-enrolled in Part 2 MK-8723 100 mg/kg \& dosed per protocol procedure.	0.00% 0/6 • Up to 84 days The APaT population consisting of all participants who received at least one dose of study drug was used for the safety analysis. AEs are presented according to the actual treatment administered (i.e., as treated). 2 participants that completed Part 2 MK-8723 10 mg/kg were re-enrolled in Part 2 MK-8723 100 mg/kg \& dosed per protocol procedure.	16.7% 1/6 • Number of events 1 • Up to 84 days The APaT population consisting of all participants who received at least one dose of study drug was used for the safety analysis. AEs are presented according to the actual treatment administered (i.e., as treated). 2 participants that completed Part 2 MK-8723 10 mg/kg were re-enrolled in Part 2 MK-8723 100 mg/kg \& dosed per protocol procedure.	0.00% 0/10 • Up to 84 days The APaT population consisting of all participants who received at least one dose of study drug was used for the safety analysis. AEs are presented according to the actual treatment administered (i.e., as treated). 2 participants that completed Part 2 MK-8723 10 mg/kg were re-enrolled in Part 2 MK-8723 100 mg/kg \& dosed per protocol procedure.	0.00% 0/3 • Up to 84 days The APaT population consisting of all participants who received at least one dose of study drug was used for the safety analysis. AEs are presented according to the actual treatment administered (i.e., as treated). 2 participants that completed Part 2 MK-8723 10 mg/kg were re-enrolled in Part 2 MK-8723 100 mg/kg \& dosed per protocol procedure.	0.00% 0/2 • Up to 84 days The APaT population consisting of all participants who received at least one dose of study drug was used for the safety analysis. AEs are presented according to the actual treatment administered (i.e., as treated). 2 participants that completed Part 2 MK-8723 10 mg/kg were re-enrolled in Part 2 MK-8723 100 mg/kg \& dosed per protocol procedure.	0.00% 0/3 • Up to 84 days The APaT population consisting of all participants who received at least one dose of study drug was used for the safety analysis. AEs are presented according to the actual treatment administered (i.e., as treated). 2 participants that completed Part 2 MK-8723 10 mg/kg were re-enrolled in Part 2 MK-8723 100 mg/kg \& dosed per protocol procedure.	0.00% 0/4 • Up to 84 days The APaT population consisting of all participants who received at least one dose of study drug was used for the safety analysis. AEs are presented according to the actual treatment administered (i.e., as treated). 2 participants that completed Part 2 MK-8723 10 mg/kg were re-enrolled in Part 2 MK-8723 100 mg/kg \& dosed per protocol procedure.
Skin and subcutaneous tissue disorders Dermatitis contact	0.00% 0/6 • Up to 84 days The APaT population consisting of all participants who received at least one dose of study drug was used for the safety analysis. AEs are presented according to the actual treatment administered (i.e., as treated). 2 participants that completed Part 2 MK-8723 10 mg/kg were re-enrolled in Part 2 MK-8723 100 mg/kg \& dosed per protocol procedure.	0.00% 0/6 • Up to 84 days The APaT population consisting of all participants who received at least one dose of study drug was used for the safety analysis. AEs are presented according to the actual treatment administered (i.e., as treated). 2 participants that completed Part 2 MK-8723 10 mg/kg were re-enrolled in Part 2 MK-8723 100 mg/kg \& dosed per protocol procedure.	16.7% 1/6 • Number of events 1 • Up to 84 days The APaT population consisting of all participants who received at least one dose of study drug was used for the safety analysis. AEs are presented according to the actual treatment administered (i.e., as treated). 2 participants that completed Part 2 MK-8723 10 mg/kg were re-enrolled in Part 2 MK-8723 100 mg/kg \& dosed per protocol procedure.	0.00% 0/6 • Up to 84 days The APaT population consisting of all participants who received at least one dose of study drug was used for the safety analysis. AEs are presented according to the actual treatment administered (i.e., as treated). 2 participants that completed Part 2 MK-8723 10 mg/kg were re-enrolled in Part 2 MK-8723 100 mg/kg \& dosed per protocol procedure.	0.00% 0/6 • Up to 84 days The APaT population consisting of all participants who received at least one dose of study drug was used for the safety analysis. AEs are presented according to the actual treatment administered (i.e., as treated). 2 participants that completed Part 2 MK-8723 10 mg/kg were re-enrolled in Part 2 MK-8723 100 mg/kg \& dosed per protocol procedure.	0.00% 0/10 • Up to 84 days The APaT population consisting of all participants who received at least one dose of study drug was used for the safety analysis. AEs are presented according to the actual treatment administered (i.e., as treated). 2 participants that completed Part 2 MK-8723 10 mg/kg were re-enrolled in Part 2 MK-8723 100 mg/kg \& dosed per protocol procedure.	0.00% 0/3 • Up to 84 days The APaT population consisting of all participants who received at least one dose of study drug was used for the safety analysis. AEs are presented according to the actual treatment administered (i.e., as treated). 2 participants that completed Part 2 MK-8723 10 mg/kg were re-enrolled in Part 2 MK-8723 100 mg/kg \& dosed per protocol procedure.	0.00% 0/2 • Up to 84 days The APaT population consisting of all participants who received at least one dose of study drug was used for the safety analysis. AEs are presented according to the actual treatment administered (i.e., as treated). 2 participants that completed Part 2 MK-8723 10 mg/kg were re-enrolled in Part 2 MK-8723 100 mg/kg \& dosed per protocol procedure.	0.00% 0/3 • Up to 84 days The APaT population consisting of all participants who received at least one dose of study drug was used for the safety analysis. AEs are presented according to the actual treatment administered (i.e., as treated). 2 participants that completed Part 2 MK-8723 10 mg/kg were re-enrolled in Part 2 MK-8723 100 mg/kg \& dosed per protocol procedure.	0.00% 0/4 • Up to 84 days The APaT population consisting of all participants who received at least one dose of study drug was used for the safety analysis. AEs are presented according to the actual treatment administered (i.e., as treated). 2 participants that completed Part 2 MK-8723 10 mg/kg were re-enrolled in Part 2 MK-8723 100 mg/kg \& dosed per protocol procedure.
Skin and subcutaneous tissue disorders Swelling face	0.00% 0/6 • Up to 84 days The APaT population consisting of all participants who received at least one dose of study drug was used for the safety analysis. AEs are presented according to the actual treatment administered (i.e., as treated). 2 participants that completed Part 2 MK-8723 10 mg/kg were re-enrolled in Part 2 MK-8723 100 mg/kg \& dosed per protocol procedure.	0.00% 0/6 • Up to 84 days The APaT population consisting of all participants who received at least one dose of study drug was used for the safety analysis. AEs are presented according to the actual treatment administered (i.e., as treated). 2 participants that completed Part 2 MK-8723 10 mg/kg were re-enrolled in Part 2 MK-8723 100 mg/kg \& dosed per protocol procedure.	0.00% 0/6 • Up to 84 days The APaT population consisting of all participants who received at least one dose of study drug was used for the safety analysis. AEs are presented according to the actual treatment administered (i.e., as treated). 2 participants that completed Part 2 MK-8723 10 mg/kg were re-enrolled in Part 2 MK-8723 100 mg/kg \& dosed per protocol procedure.	16.7% 1/6 • Number of events 1 • Up to 84 days The APaT population consisting of all participants who received at least one dose of study drug was used for the safety analysis. AEs are presented according to the actual treatment administered (i.e., as treated). 2 participants that completed Part 2 MK-8723 10 mg/kg were re-enrolled in Part 2 MK-8723 100 mg/kg \& dosed per protocol procedure.	0.00% 0/6 • Up to 84 days The APaT population consisting of all participants who received at least one dose of study drug was used for the safety analysis. AEs are presented according to the actual treatment administered (i.e., as treated). 2 participants that completed Part 2 MK-8723 10 mg/kg were re-enrolled in Part 2 MK-8723 100 mg/kg \& dosed per protocol procedure.	0.00% 0/10 • Up to 84 days The APaT population consisting of all participants who received at least one dose of study drug was used for the safety analysis. AEs are presented according to the actual treatment administered (i.e., as treated). 2 participants that completed Part 2 MK-8723 10 mg/kg were re-enrolled in Part 2 MK-8723 100 mg/kg \& dosed per protocol procedure.	0.00% 0/3 • Up to 84 days The APaT population consisting of all participants who received at least one dose of study drug was used for the safety analysis. AEs are presented according to the actual treatment administered (i.e., as treated). 2 participants that completed Part 2 MK-8723 10 mg/kg were re-enrolled in Part 2 MK-8723 100 mg/kg \& dosed per protocol procedure.	0.00% 0/2 • Up to 84 days The APaT population consisting of all participants who received at least one dose of study drug was used for the safety analysis. AEs are presented according to the actual treatment administered (i.e., as treated). 2 participants that completed Part 2 MK-8723 10 mg/kg were re-enrolled in Part 2 MK-8723 100 mg/kg \& dosed per protocol procedure.	0.00% 0/3 • Up to 84 days The APaT population consisting of all participants who received at least one dose of study drug was used for the safety analysis. AEs are presented according to the actual treatment administered (i.e., as treated). 2 participants that completed Part 2 MK-8723 10 mg/kg were re-enrolled in Part 2 MK-8723 100 mg/kg \& dosed per protocol procedure.	0.00% 0/4 • Up to 84 days The APaT population consisting of all participants who received at least one dose of study drug was used for the safety analysis. AEs are presented according to the actual treatment administered (i.e., as treated). 2 participants that completed Part 2 MK-8723 10 mg/kg were re-enrolled in Part 2 MK-8723 100 mg/kg \& dosed per protocol procedure.

Additional Information

Senior Vice President, Global Clinical Development

Merck Sharp & Dohme Corp.

Phone: 1-800-672-6372

Email: [email protected]

Results disclosure agreements

Principal investigator is a sponsor employee The Sponsor must have the opportunity to review all proposed abstracts, manuscripts or presentations regarding this trial 45 days prior to submission for publication/presentation. Any information identified by the Sponsor as confidential must be deleted prior to submission; this confidentiality does not include efficacy and safety results.
Publication restrictions are in place

Restriction type: OTHER